Professional Experience CV_3... · Web viewMeenhard Herlyn, D.V.M, D.Sc. Updated: 3/18/15. Home Address. 1223 Knox Road. Wynnewood, PA 19096. Office Address. The Wistar Institute

Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.

Meenhard Herlyn, D.V.M, D.Sc.

Updated: 3/18/15

Home Address1223 Knox RoadWynnewood, PA 19096

Office AddressThe Wistar Institute3601 Spruce StreetPhiladelphia, PA 19104 USATel.: 215-898-3950Fax: 215-898-0980Email: [email protected]: http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc

EDUCATION1970 D.V.M., Veterinary Medical School, Hannover, Germany1976 D.Sc., Medical Microbiology, University of Munich, Germany

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS1971-1972 Fellowship in Immunology and Virology, University of Munich, Germany1972-1976 Assistant at the Institute of Medical Microbiology, Infectious and Epidemic

Diseases, Veterinary Faculty, Maximillian University, Munich, Germany1976-1979 Associate Scientist, The Wistar Institute, Philadelphia, PA1979-1981 Research Associate, The Wistar Institute, Philadelphia, PA1981-1985 Assistant Professor, The Wistar Institute, Philadelphia, PA1986-1990 Associate Professor, The Wistar Institute, Philadelphia, PA1991-present Professor, The Wistar Institute, Philadelphia, PA1991-1993 Chairman, Program of Experimental Therapeutics, The Wistar Institute,

Philadelphia, PA1993-1998 Chairman, Program of Molecular and Cellular Biology, The Wistar Institute,

Philadelphia, PA1998-2002 Chairman, Tumor Biology Program, The Wistar Institute, Philadelphia, PA2002-2012 Leader, Molecular and Cellular Oncogenesis Program, The Wistar Institute,

Philadelphia, PA2008-2011 Associate Director for Translational Research, The Wistar Institute2010-present Director, Melanoma Research Center, Philadelphia, PA2011-present Caspar Wistar Professor in Melanoma Research, Philadelphia, PA

FACULTY APPOINTMENTS1982-1996 Consultant, Adjunct Associate Professor of Gynecology, Adjunct Professor of

Gynecology, Dept. of Gynecology, Division of Surgery, University of Texas, MD Anderson Cancer Center, Houston, TX

1989-1991 Wistar Institute Associate Professor of Dermatology and Wistar Institute Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia

1989-present Member, Cellular and Molecular Biology Graduate Program (CAMB), University of Pennsylvania, Philadelphia

1991- present Member, University of Pennsylvania Comprehensive Cancer Center, Philadelphia1992-present Wistar Institute Professor of Dermatology and Wistar Institute Professor of

Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia1995-2002 Member, Institute for Human Gene Therapy, University of Pennsylvania,

Philadelphia1

mailto:[email protected]


2007-present

2011-present

Member, Bioengineering Graduate Group, University of Pennsylvania, PhiladelphiaMember, Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia

AWARDS AND HONORS2004 Wings of Hope, Diana Ashby Award for Excellence in Melanoma Research

(Melanoma Research Foundation)2005 American Skin Association Annual Skin Cancer/Melanoma Achievement Award2006 Scientific Research Award for Outstanding Contributions in Melanoma Research,

American Cancer Society, Southeast Region, Pennsylvania Division2006 7th Annual Wallace H. Clark, Jr., M.D., Lectureship in Cutaneous Oncology,

University of Pennsylvania, Philadelphia2007 Pan American Pigment Cell Society Achievement Award2007 Lifetime Achievement Award in Melanoma Research (Society for Melanoma

Research)2008 28th Alfred-Marchioni Memorial Award, Hamburg, Germany2008 Joseph-von-Plenck Award, Austrian Society for Dermatology and Venereology,

Vienna Austria2010 Award for Lifetime Achievement in Melanoma Research (Society for Melanoma

Research)2013 Rod and Ceil Mortel Visiting Scholar in Cancer Research, Penn State Milton S.

Hershey Medical Center, Penn State College of Medicine, Hershey, PA2013 Founder’s Award (Society for Melanoma Research)2014 International Skin Carcinogenesis Conference Keynote Lecture Award2014 Wings of Hope, Humanitarian Award (Melanoma Research Foundation)2015 American Skin Association, Life Time Research Achievement Award

MEMBERSHIPS IN: PROFESSIONAL AND SCIENTIFIC SOCIETIES (including offices held):1982-present American Association for Cancer Research

1996-2002, Pennsylvania Steering Committee1997, Program Committee Chair, Biology2004-2005, Stem Cell Initiative

1984-2010 American Association for Investigative Pathology1995-present Society for Investigative Dermatology1999-present Pan American Society for Pigment Cell Research

1999-2002, Council Member1999-2002, Melanoma Group Chair2000-2002, Membership Committee

1999-present International Federation of Pigment Cell Societies1999-2003, Special Interest Group on ‘Biology of Melanoma’ Chair

1985-present American Association for the Advancement of Science2000-present Metastasis Research Society2004-present Society for Melanoma Research

2004-2007, Founder and President2004-2007, Ex officio member of Executive Committee, Steering Committee (Chair), Meeting Committee, Finance Committee, Election Committee, Membership Committee2007-2010, Past President, Member Steering Committee

2006-20112010-present

Society for Stem Cell ResearchAmerican Society for Clinical Oncology

EDITORIAL POSITIONS1986-1988 Editorial Board, The Journal of Clinical Laboratory Analysis1990-present Associate Editor, Melanoma Research

2


1992-1998 Editorial Board, Cell Growth and Differentiation1994-1999 Associate Editor, Pigment Cell Research1995-2003 Associate Editor, Journal of Experimental Therapeutics and Oncology1995-2002 Editorial Board, Pathology Oncology Research1997-2004 Editorial Board, American Journal of Pathology1998-2000 Editorial Board, Tumor Targeting2000-2007 Editorial Board, Cancer Research2001-present Editorial Board, Cancer Biology and Therapy2002-present Editorial Board, Cancer and Metastasis Review, 2005 Guest Editor2002-2007 Associate Editor, Journal of Investigative Dermatology2005-present Associate Editor, Pigment Cell and Melanoma Research2005-present Editorial Board, International Journal of Cancer2007-present Section Editor, Journal of Investigative Dermatology2007-present Scientific Advisory Board, Journal of Cell Communication and Signaling2007-present Consulting Editorial Board, Journal of Clinical Investigation2007-present Editorial Board, Open Dermatology Journal2008-present Editorial Board, Journal of Oncology2008-present Editorial Board, Experimental Dermatology2009-present Editorial Board, Genes & Cancer2010-2011 Editorial Board, PLoS One2012-present Editorial Board, Cancer Biomarkers2013-present Editorial Board, Melanoma Management2013-present Editorial Board, Precision Oncology2013-present Advisory Board, International CCN Society

MANUSCRIPT REVIEWERWith major support from laboratory members, review of 110-170 manuscripts per year (2000-present) for the American Journal of Pathology, Archives of Dermatology, Cancer, Cancer Cell, Cancer Research, Cell, Clinical Cancer Research, Experimental Cell Research, International Journal of Cancer, Journal of Cell Science, Journal of Clinical Investigations, Journal of Investigative Dermatology, Journal of Immunology, Journal of Experimental Medicine, Laboratory Investigation, Melanoma Research, Molecular Carcinogenesis, Nature, Nature Cell Biology, Nature Medicine, Nature Review Cancer, Oncogene, Pigment Cell Melanoma Research, Proceedings National Academy of Sciences (USA), and Science.

3


LECTURES BY INVITATION (past 5 years)

2010 Jan. 11 University of Vienna, Vienna, AustriaJan. 14 L’Oreal, Paris, FranceFeb. 23 University of North Carolina, Chapel Hill, NCMarch 2 University of Pittsburgh, Pittsburgh, PAMarch 31 University of California at Irvine, Irvine, CAApril 30 Moffitt Cancer Center, Tampa, FLMay 28 Schering-Plough, Kenilworth, NJJune 2 MD Anderson Cancer Center, SPORE Symposium, Houston, TXJune 24 GenoMEL, University of Leeds, Leeds, GBJune 26 Human Skin Carcinogenesis Symposium, Collegeville, PAAugust 2 Roswell Park Memorial Institute, Buffalo, NYSept. 12 AACR TME and Metastasis, Philadelphia, PANov. 2 Centenary Institute, University of Sydney, Sydney, AustraliaNov. 5 SMR 7th International Conference, Sydney, AustraliaNov. 9 Melanoma Symposium, Western Australia Institute for Medical

Research, Perth, AustraliaDec. 14 University of Ohio, Cincinnati, OH

2011 Jan. 12 MD Anderson Cancer Center, Science Park, TXJan. 28 L’Oreal, Paris, FranceFeb. 2 Adelson Medical Research Foundation, Las Vegas, NVFeb. 18 Melanoma Research Alliance, Washington, DC, Session ChairMarch 7 AACR Special Conference on Stem Cells, Differentiations and Cancer,

Vancouver, Canada, Session ChairMarch 23 Banbury Meeting on Curing Melanoma, Cold Spring Harbor Laboratory,

NY, Session Chair April 2-4 AACR Annual Meeting, Orlando, FLApril 27 CSHL Symposium on Tumor Microenvironment, Cold Spring Harbor,

NYMay 5 Tetralogic, Malvern, PAMay 25 World Congress of Dermatology, Seoul, KoreaJune 27 Engineered Tissue Models for Environmental Health Science Research,

NIEHS, Research Triangle Park, Chapel Hill, NCJuly 10 European Post-ASCO Meeting, Munich, GermanyNov. 29 National Cancer Institute, Bethesda, MDDec. 8 L’Oreal Inc., Paris, FranceDec. 16 Expert Forum on Malignant Melanoma, Los Angeles, CA

2012 Jan. 19 Virginia Commonwealth University, Richmond, VAFeb. 2Feb. 21April 1

Dartmouth School of Medicine, Dartmouth, NHGerman Cancer Congress, Berlin, Germany, Keynote LectureAmerican Association for Cancer Research, Annual Meeting, Major Symposium Speaker

May 10 AACR Special Conference on Resistance Mechanisms to Targeted Therapy, San Diego, CA

June Melanoma Research Foundation Breakthrough Consortium, Chicago, IL

June 12 Genentech, San Francisco, CAJune 18 GenoMEL Annual Symposium, Leiden, NetherlandsJune 22 Pigment Cell and Melanoma Research Symposium, NCI, Bethesda,

MDJuly 27 SPORE in Skin Cancer, Yale University, New Haven, CT

4


August 13 University of Cologne, Cologne, GermanySept. 5 L’Oreal Inc., Paris, France

2013 Jan. 25 Sandford-Burnham Institute, La Jolla, CAMarch 22 German Cancer Society, Heidelberg, GermanyMay 2 Hershey Medical Center, Hershey, PA, Award LectureMay 8 International Melanoma Congress, Dublin, IrelandSept. 5 Brazilian Workshop on Melanoma, São Paulo, Brazil, Keynote LectureSept. 10 European Organization of Pigment Cell Research, Lisbon, Portugal,

Keynote LectureSept. 17 L’Oreal Inc., Paris, FranceSept. 27 Temple University, Philadelphia, PANov. 20 SMR 10th International Congress, Philadelphia, PA, co-organizer

2014 Jan. 29Febr. 27March 9April 5April 11April 25June 5Sept. 4

University of University of Iowa, Iowa City, IOMelanoma Research Alliance, Washington, DCTumor Progression and Therapeutic Resistance, Boston, MAAmerican Association for Cancer Research (AACR), San Diego, CAHemOnc Today: Melanoma and Cutaneous Oncology, New York, NYGeorgia Regents University, Augusta, GAInternational Skin Cancer Conference, Tucson, AZ, Keynote lectureWorld Skin Cancer Congress, Edinburgh, GB

Sept. 22 AACR Melanoma Conference, Philadelphia, PAOct. 10 Australian Melanoma Conference, Perth, Australia, Keynote Lecture

Oct. 13 University of Queensland, Brisbane, Australia

2015Feb. 10 Melanoma Club, Mt. Sinai, New York, NY

ADVISORY ROLES (past 10 years):2008-2011 MRF, Board of Managers, Member

2009 Jan., Southwestern Melanoma SPORE, Denver, CO, External Advisor

Jan., PO1 Biotherapy of Metastatic Melanoma: Biology and Systemic Delivery of MDA7/IL-24, (E. Grimm, PI), MD Anderson Cancer Center, Houston, TX, External Advisor

Feb., Oct., NCI Study Sections, Tumor Microenvironment (TME), Ad Hoc

May, NCI Intramural Review, Laboratory of Cancer PreventionJuly, NCI, Stage II Challenge Grant Review Committee, Ad HocOct., Utah Skin SPORE, External AdvisorFeb.-Dec., Grant Reviews for Funding Agencies in Netherlands,

Austria, Australia, Germany, Israel, Great Britain Australia, Germany, Israel, Great Britain

2010 Joanna M. Nikolay Melanoma Foundation, Advisory BoardNDRI, Board of Directors, ChairNCI, Feb., Oct., TME Study Section, Member NCI, Special Emphasis Panel, ChairMRA, Grant Review Committee, Co-ChairRoche, Washington, DC, AdvisorMoffitt Cancer Center, Tampa, FL, SPORE AdvisorMRF Breakthrough Consortium, Board of Directors

5


MRF Breakthrough Consortium, Secretary Treasurer

2011 Melanoma Research Alliance, Scientific Review Committee Co-ChairJune, Tumor Microenvironment Network Study Section, NCI, ChairSept., SPORE Study Section, Ad HocOct., TME NCI Study Section, MemberJan.-Dec., Grant reviews from Austria, Germany, New Zealand, Israel,

Ireland, Netherlands, NorwayGrant Reviews for the Melanoma Research Foundation, Joanna

Nicolay Melanoma FoundationNDRI, Board of Directors, ChairMRF Breakthrough Consortium, Board of Directors

2013

2014

Feb., Melanoma Research Alliance, Scientific Review Committee, MemberMay, NCI, Special Emphasis Panel, Ad Hoc ReviewerApril., Melanoma Research Foundation, ReviewerAugust, Melanoma Research FoundationNDRI, Board of Directors, ChairMD Anderson, Skin SPOREMRF Breakthrough Consortium, Board of DirectorsSMR Congress 2013, Co-OrganizerProgram Project, MD Anderson, L. Chin, PI

Febr. Melanoma Research Foundation, ReviewerApril, Melanoma Research FoundationNDRI, Board of Directors, ChairMD Anderson, Skin SPOREMRF Breakthrough Consortium, Board of DirectorsLung Cancer Spore, Denver, CO

FUNDINGTargeted Therapies in MelanomaPrincipal Investigator: Meenhard HerlynAgency: National Cancer InstituteType: PO1 (CA114046-03)Years 5-10, Period: May 16, 2008 to Oct. 1, 2018Subproject 1: Senescence as an endpoint in melanoma therapy

Human Melanoma: Etiology, Progression, and TherapyPrincipal Investigator: Meenhard HerlynAgency: NIH/NCIType: P01-Program Project (CA25874), Years 30-34, Period: May 1, 2011 to April 30, 2016 Subproject on grant: Cellular mechanisms of therapy resistance

Biology of Melanoma MetastasisPrincipal Investigator: Meenhard HerlynAgency: National Cancer InstituteType: R01 (CA47159)Years 21-25, 2011-2016

Cell-Cell Communication During Melanoma ProgressionPrincipal Investigator: Meenhard HerlynAgency: National Cancer Institute

6


Type: R01 (CA76674)Years 15-19, Period: April 1, 2011 to March 31, 2016

The Role of Genetic Susceptibility in Melanoma DevelopmentPrincipal Investigator: Meenhard HerlynAgency: National Cancer InstituteType: R01 (CA182890)Years 1-5, Period: May 1, 2014 to April. 30, 2019

SPORE in Skin CancerPrincipal Investigator: Meenhard HerlynAgency: National Cancer InstituteType: SPORE (CA174523)Years 1-5, Period: September 16, 2014 to September 15, 2019

CORE ACTIVITIES1.Administrative Core A for Human Melanoma – Etiology, Progression & Therapy (CA025874)2. Administrative Core A for Targeted Therapies in Melanoma (CA114046) 3. Administrative Core A for SPORE in Skin Cancer (CA174523) 4. Cell Biology Core C for Targeted Therapies in Melanoma (CA114046)

2013: Sponsored Agreements with industry (GSK, Novartis, Plexxikon, Tetralogic)

Dr. Miriam and Sheldon Adelson Foundation for Medical Research (2013/14) Melanoma Research Alliance (Team Award) (2013-16) Melanoma Research Foundation (2013/14)

BIBLIOGRAPHY Research Publications, Peer Reviewed1. Buschmann H, Herlyn M. Stimulation of phagocytic activity by dextran. Z Immunitatsforsch Exp

Klin Immunol. 1972;143:209-210. PMID4282799 2. Mayr A, Streitferdt U, Herlyn M, Jaeger O. Vaccination of dogs against rabies. Die Kleintierpraxis.

1973;18:91-96. 3. Danner K, Herlyn M, Gerbermann H, Mayr A. Oral immunization against pox. 5: effectiveness of

drinking water vaccination against fowl pox. Zentralbl Veterinärmed B. 1975;22:274-284. PMID169653

4. Mahnel H, Herlyn M. Stability of Teschen, HCC, ND and vaccinia viruses against 5 disinfectants. Zentralbl Veterinärmed B. 1976;23:403-411. PMID183417

5. Mahnel H, Ottis K, Herlyn M. Stability in drinking and surface water of nine virus species from different genera (author’s transl). Zentralbl Bakteriol [Orig B]. 1977;164:64-84. PMID14460

6. Danner K, Luthgen K, Herlyn M, Mayr A. Comparative studies on the demonstration and formation of serum antibodies against the Borna virus. Zentralbl Veterinärmed B. 1978;25:345-355. PMID358683

7. Koprowski H, Steplewski Z, Herlyn D, Herlyn M. Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A. 1978;75:3405-3409. PMID80012 (PMC392785)

8. Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol. 1979;9:657-659. PMID499332

9. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979;76:1438-1442. PMID286328 (PMC383267)

10. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957-971. PMID94699

7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=94699










11. Steplewski Z, Herlyn M, Herlyn D, Clark WH, Koprowski H. Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. Eur J Immunol. 1979;9:94-96. PMID374094

12. Herlyn M, Clark WH Jr, Mastrangelo MJ, Guerry DT, Elder DE, LaRossa D, Hamilton R, Bondi E, Tuthill R, Steplewski Z, Koprowski H. Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res. 1980;40:3602-3609. PMID6159966

13. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980;40:717-721. PMID7471090

14. Wittek R, Herlyn M, Schumperli D, Bachmann PA, Mayr A, Wyler R. Genetic and antigenic heterogeneity of different parapoxvirus strains. Intervirology. 1980;13:33-41. PMID6153643

15. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53-55. PMID6163212

16. Mayr A, Herlyn M, Mahnel H, Danco A, Zach A, Bostedt H. Control of ecthyma contagiosum (pustular dermatitis) of sheep with a new parenteral cell culture live vaccine. Zentralbl Veterinarmed B. 1981;28:535-552. PMID7331595

17. Sears HF, Herlyn D, Herlyn M, Grotzinger PJ, Steplewski Z, Gerhard W, Koprowski H. Ex vivo perfusion of a tumor-containing colon with monoclonal antibody. J Surg Res. 1981;31:145-150. PMID6790874

18. Steplewski Z, Chang TH, Herlyn M, Koprowski H. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells. Cancer Res. 1981;41:2723-2727. PMID7248940

19. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res. 1982;42:4820-4823. PMID6751528

20. Brockhaus M, Magnani JL, Herlyn M, Blaszczyk M, Steplewski Z, Koprowski H, Ginsburg V. Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are obtained from mice immunized with human tumors. Arch Biochem Biophys. 1982;217:647-651. PMID7138030

21. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol. 1982;2:135-140. PMID7068815

22. Herlyn M, Steplewski Z, Atkinson BF, Ernst CS, Koprowski H. Comparative study of the binding characteristics of monoclonal antimelanoma antibodies. Hybridoma. 1982;1:403-411. PMID6765323

23. Sears HF, Herlyn M, Del Villano B, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol. 1982;2:141-149. PMID7068816

24. Sears HF, Herlyn D, Herlyn M, Steplewski Z, Grotzinger P, Koprowski H. Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies. Cancer. 1982;49:1231-1235. PMID7059945

25. Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors. Am J Pathol. 107:357-361. PMID6177248 (PMC1916245)

26. Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Expression of DR antigens in freshly frozen human tumors. Hybridoma. 1982;1:161-168. PMID6208123

27. Folberg R, Donoso LA, Herlyn MF, Koprowski H. Antigens in ocular and cutaneous melanomas. Am J Ophthalmol. 1983;96:394-395. PMID6351625

28. Hansson GC, Karlsson KA, Larson G, McKibbin JM, Blaszczyk M, Herlyn M, Steplewski Z, Koprowski H. Mouse monoclonal antibodies against human cancer cell lines with specificities for blood group and related antigens; characterization by antibody binding to glycosphingolipids in a chromatogram binding assay. J Biol Chem. 1983;258:4091-4097. PMID6833243

29. Herlyn M, Herlyn D, Elder DE, Bondi E, LaRossa D, Hamilton R, Sears HF, Balaban G, Guerry D, Clark WH, Kaprowski H. Phenotypic characteristics of cells derived from precursors of human melanoma. Cancer Res. 1983;43:5502-5508. PMID6616481

8





















30. Herlyn D, Powe J, Alavi A, Mattis JA, Herlyn M, Ernst CS, Vaum R, Koprowski H. Radioimmunodetection of human tumor xenografts by monoclonal antibodies. Cancer Res. 1983;43:2731-2735. PMID6342757

31. Herlyn M, Steplewski Z, Herlyn D, Clark WH Jr, Ross AH, Blaszczyk M, Pak KY, Koprowski H. Production and characterization of monoclonal antibodies against human malignant melanoma. Cancer Invest. 1983;1:215-224. PMID6667406

32. Herlyn M, Blaszczyk M, Sears HF, Verrill H, Lindgren J, Colcher D, Steplewski Z, Schlom J, Koprowski H. Detection of carcinoembryonic antigen and related antigens in sera of patients with gastrointestinal tumors using monoclonal antibodies in double-determinant radioimmunoassays. Hybridoma. 1983;2:329-339. PMID6205981

33. Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J, Berche C, Douillard JY, Carrel S, Herlyn M, Stepiewski Z, Koprowski H. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res. 1983;43:5593-5600. PMID6616486

34. Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z, Koprowski H. Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys. 1983;225:370-383. PMID6614928

35. Steplewski Z, Herlyn M, Blaszczyk M, Koprowski H. A simple procedure for determining Lewis phenotypes in human saliva. J Immunol Methods. 1983;62:73-78. PMID6348171

36. Zehngebot LM, Alexander MA, Guerry DT, Cines DB, Mitchell K, Herlyn M. Functional consequence of variation in melanoma antigen expression. Cancer Immunol Immunother. 1983;16:30-34. PMID6605801

37. Atkinson B, Ernst CS, Ghrist BF, Herlyn M, Blaszczyk M, Ross AH, Herlyn D, Steplewski Z, Koprowski H. Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res. 1984:44:2577-2581. PMID6722794

38. Balaban G, Herlyn M, Guerry DT, Bartolo R, Koprowski H, Clark WH, Nowell PC. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet. 1984;11:429-439. PMID6584203

39. Blaszczyk M, Hansson GC, Karlsson KA, Larson G, Stromberg N, Thurin J, Herlyn M, Steplewski Z, Koprowski H. Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies. Arch Biochem Biophys. 1984;233:161-168. PMID6465894

40. Blaszczyk M, Pak KY, Herlyn M, Lindgren J, Pessano S, Steplewski Z, Koprowski H. Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens defined by monoclonal antibodies. Cancer Res. 1984;44:245-253. PMID6360346

41. Donoso LA, Folberg R, Angiolillo P, Herlyn M. A 19-9 monoclonal antibody study of adenocarcinoma metastatic to the choroid. Am J Ophthalmol. 1984;98:815-816. PMID6507563

42. Ernst CS, Thurin J, Atkinson B, Wurzel H, Herlyn M, Stromberg N, Civin C, Koprowski H. Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed human tissues. Am J Pathol. 1984;117:451-461. PMID6507589

43. Ernst CS, Atkinson B, Wysocka M, Blaszczyk M, Herlyn M, Sears H, Steplewski Z, Koprowski H. Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab Invest. 1984;50:394-400. PMID6368970 (PMC1900579)

44. Guerry DT, Alexander MA, Herlyn MF, Zehngebot LM, Mitchell KF, Zmijewski CM, Lusk EJ. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest. 1984;73:267-271. PMID6606651

45. Herlyn M, Sears HF, Verrill H, Koprowski H. Increased sensitivity in detecting tumor-associated antigens in sera of patients with colorectal carcinoma. J Immunol Methods. 1984;75:15-21. PMID6512262

46. Herlyn D, Herlyn M, Ross AH, Ernst CS, Atkinson B, Koprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods. 1984;73:157-167. PMID6491298

47. Herlyn M, Lange B, Bennicelli J, Blaszczyk M, Guerry DT, Koprowski H. Increased levels of circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia. Leuk Res. 1984;8:323-334. PMID6431198

9




















48. Herlyn M, Shen JW, Sears HF, Civin CI, Verrill HL, Goldberg EM, Koprowski H. Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by a double determinant immunoassay with monoclonal antibodies against human blood group determinants. Clin Exp Immunol. 1984;55:23-35. PMID6198117 (PMC1535790)

49. Miller SL, Pleasure D, Herlyn M, Atkinson B, Ernst CS, Tachovsky TG, Baird L. Production and characterization of monoclonal antibodies to peripheral and central nervous system myelin. J Neurochem. 1984;43:394-400. PMID6204014

50. Pak KY, Blaszczyk M, Herlyn M, Steplewski Z, Koprowski H. Identification and isolation of Lewis blood group antigens from human saliva using monoclonal antibodies. Hybridoma. 1984;3:1-10. PMID6469267

51. Pegg AE, Seely JE, Persson L, Herlyn M, Ponsell K, O’Brien TG. Studies of mammalian ornithine decarboxylase using a monoclonal antibody. Biochem J. 1984;217:123-128. PMID6421279 (PMC1153189)

52. Ross AH, Grob P, Bothwell M, Elder DE, Ernst CS, Marano N, Ghrist BF, Slemp CC, Herlyn M, Atkinson B, Koprowski H. Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A. 1984;81:6681-6685. PMID6093111 (PMC391994)

53. Ross AH, Herlyn M, Ernst CS, Guerry D, Bennicelli J, Ghrist BF, Atkinson B, Koprowski H. Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodies. Cancer Res. 1984;44:4642-4647. PMID6380710

54. Verrill H, Goldberg M, Kovac G, Atkinson B, Herlyn M. Evaluation of monoclonal antibody to 19-9 antigen as a potential screening technique for colorectal cancer in a high-risk population. Prog Clin Biol Res. 1984;156:107-114. PMID6382320

55. Atkinson B, Ernst CS, Ghrist BF, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z, Koprowski H. Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma. 1985;4:243-255. PMID4043988

56. Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z. Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas. Proc Natl Acad Sci U S A. 1985;82:3552-3556. PMID2582419 (PMC397823)

57. Donoso LA, Folberg R, Edelberg K, Arbizo V, Atkinson B, Herlyn M. Tissue distribution and biochemical properties of an ocular melanoma-associated antigen. J Histochem Cytochem. 1985;33:1190-1196. PMID3905953

58. Folberg R, Donoso LA, Atkinson BF, Ernst CS, Herlyn M, Arbizo VV. An antimelanoma monoclonal antibody and the histopathology of uveal melanomas. Arch Ophthalmol. 1985;103:275-279. PMID2579631

59. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, Koprowski H. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985;45:5670-5676. PMID4053039

60. Herlyn M, Blaszczyk M, Bennicelli J, Sears HF, Ernst CS, Ross AH, Koprowski H. Selection of monoclonal antibodies detecting serodiagnostic human tumor markers. J Immunol Methods. 1985;80:107-116. PMID3859550

61. Herlyn M, Guerry D, Koprowski H. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol. 1985;134:4226-4230. PMID2985706

62. Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol. 1985;92:105-114. PMID4075410

63. Herlyn D, Powe J, Ross AH, Herlyn M, Koprowski H. Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells. J Immunol. 1985;134:1300-1304. PMID3965572

64. Herlyn M, Balaban G, Bennicelli J, Guerry DT, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell PC. Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst. 1985;74:283-289. PMID3856042

10



















65. Koprowska I, Zipfel SA, Himes TR, Herlyn M. Common antigenic sites on exfoliated cells derived from cervical carcinoma and in tumor cells of nonuterine origin as demonstrated by monoclonal antibodies in immunoperoxidase assay. Cancer Res. 1985;45:5964-5968. PMID2414003

66. Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, Nowell P. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet. 1985;11:297-302. PMID2988138

67. Matera L, Francis MK, Herlyn M, Trucco M, Santoli D. Generation of natural killer-like activity in mixed lymphocyte-tumor cell cultures. I. Role of HLA-DR antigens as stimulatory molecules. Nat Immun Cell Growth Regul. 1985;4:90-102. PMID3160934

68. Sears HF, Shen JW, Herlyn M, Atkinson B, Engstrom PF, Koprowski H. Circulating tumor markers and assessment of response to intrahepatic chemotherapy of colon carcinoma. Am J CIin Oncol. 1985;8:108-117. PMID2929709

69. Thurin J, Herlyn M, Hindsgaul O, Stromberg N, Karlsson KA, Elder D, Steplewski Z, Koprowski H. Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. J Biol Chem. 1985;260:14556-14563. PMID4055789

70. Balaban GB, Herlyn M, Clark WH Jr, Nowell PC. Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet. 1986;19:113-122. PMID3940171

71. Donoso LA, Felberg NT, Edelberg K, Borlinghaus P, Herlyn M. Metastatic uveal melanoma: an ocular melanoma associated antigen in the serum of patients with metastatic disease. J Immunoassay. 1986;7:273-283. PMID3805289

72. Ernst CS, Shen JW, Litwin S, Herlyn M, Koprowski H, Sears HF. Multiparameter evaluation of the expression in situ of normal and tumor-associated antigens in human colorectal carcinoma. J Natl Cancer Inst. 1986;77:387-395. PMID3461200

73. Ernst CS, Sears HF, Herlyn M, Herlyn D, Steplewski Z, Koprowski H. Detection of murine immunoglobulin in human tissues following therapeutic infusion of monoclonal antibody. Hybridoma. 1986;5(suppl 1):S79-86. PMID3527948

74. Ernst CS, Atkinson B, Chianese D, Peters J, Perry M, Herlyn M, Koprowski H. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen. Appl Pathol. 1986;4:115-124. PMID2885017

75. Herlyn D, Powe J, Munz DL, Alavi A, Herlyn M, Meinken GE, Srivastava SC, Koprowski H. Radioimmunodetection of human tumor xenografts by monoclonal antibody F(ab’)2 fragments. Int J Rad Appl Instrum B. 1986;13:401-405. PMID3793494

76. Koprowska I, Zipfel S, Ross AH, Herlyn M. Development of monoclonal antibodies that recognize antigens associated with human cervical carcinoma. Acta Cytol. 1986;30:207-213. PMID3521172

77. Parmiter AH, Balaban G, Herlyn M, Clark WH Jr, Nowell PC. A t(1;19) chromosome translocation in three cases of human malignant melanoma. Cancer Res. 1986;46:1526-1529. PMID3943110

78. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci U S A. 1986;83:3728-3732. PMID3012531 (PMC323596)

79. Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H. Mechanisms of tumor growth inhibition. Hybridoma. 1986;5(suppl 1):S59-64. PMID3744386

80. Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH Jr, Koprowski H. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett. 1986;208:17-22. PMID3533633

81. Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin CH, Herlyn M, Rodeck U, Koprowski H. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A.1986;83:7197-7200. PMID3020539 (PMC386682)

82. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L, Das M. Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res. 1987;47:2531-2536. PMID2436750

83. Guerry DT, Herlyn MF, Elder DE, Herlyn MF. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol. 1987;139:305-312. PMID3108402

11





















84. Herlyn M, Rodeck U, Mancianti M, Cardillo FM, Lang A, Ross AH, Jambrosic J, Koprowski H. Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture. Cancer Res. 1987;47:3057-3061. PMID3034401

85. Menssen HD, Herlyn M, Rodeck U, Koprowski H. Rapid dissociation of adherent human tumor cells by ultrasound. J Immunol Methods. 1987;104:1-6. PMID3316390

86. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys. 1987;252:549-560. PMID2434025

87. Ordonez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol. 1987;26:1-10. PMID2431961

88. Rodeck U, Herlyn M, Koprowski H. Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem. 1987;35:315-320. PMID2831241

89. Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer. 1987;40:687-690. PMID3316051

90. Rodeck U, Herlyn M, Leander K, Borlinghaus P, Koprowski H. A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma. 1987;6:389-401. PMID2442094

91. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res. 1987;47:3692-3696. PMID3297307

92. Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, Smereczynska M, Karlsson KA, Clark WM Jr, Steplewski Z, Koprowski H. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res. 1987;47:1229-1233. PMID3815333

93. Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S. Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol. 1987;138:1310-1316. PMID3100635

94. Herlyn M, Mancianti ML, Jambrosic J, Bolen JB, Koprowski H. Regulatory factors that determine growth and phenotype of normal human melanocytes. Exp Cell Res. 1988;179:322-331. PMID2461309

95. Linnenbach AJ, Huebner K, Reddy EP, Herlyn M, Parmiter AH, Nowell PC, Koprowski H. Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. Proc Natl Acad Sci U S A. 1988;85:74-78. PMID2829178 (PMC279484)

96. Mancianti ML, Herlyn M, Weil D, Jambrosic J, Rodeck U, Becker D, Diamond L, Clark WH, Koprowski H. Growth and phenotypic characteristics of human nevus cells in culture. J Invest Dermatol.1988;90:134-141, 1988. PMID2828480

97. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H. Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res. 1988;48:7200-7206. PMID2461254

98. Williams NW, Rodeck U, Daly JM, Herlyn M. Growth regulatory factors for human colorectal carcinoma cells in vitro. Surgical Forum. 1988;39:445-447.

99. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo J. 1989;8:3685-3691. PMID2684645 (PMC402051)

100. Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res. 1989;49:6840-6844. PMID2582430

101. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res. 1989;49:5091-5096. PMID2548711

12


















102. Iliopoulos D, Ernst CS, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH Jr, Koprowski H, Herlyn D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440-444. PMID2918552

103. Jambrosic J, Mancianti ML, Ricciardi R, Sela BA, Koprowski H, Herlyn M. Transformation of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40 hybrid virus. Int J Cancer. 1989;44:1117-1123. PMID2558080

104. Kraemer KH, Herlyn M, Yuspa SH, Clark WH Jr, Townsend GK, Neises GR, Hearing VJ. Reduced DNA repair in cultured melanocytes and nevus cells from a patient with xeroderma pigmentosum. Arch Dermatol. 125:263-268, 1989. PMID2913963

105. Strom BL, Iliopoulos D, Atkinson B, Herlyn M, West SL, Maislin G, Saul S, Varello MA, Rodriguez-Martinez HA, Rios-Dalenz J. Pathophysiology of tumor progression in human gallbladder: flow cytometry, CEA, and CA 19-9 levels in bile and serum in different stages of gallbladder disease. J Natl Cancer Inst. 1989;81:1575-1580. PMID2795683

106. Wolf BC, Salem RR, Sears HF, Horst DA, Lavin PT, Herlyn M, Itzkowitz SH, Schlom J, Steele GD Jr. The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution. Am J Pathol. 1989;135:111-119. PMID2476033 (PMC1880239)

107. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990;50:6757-6764. PMID2208139

108. Becker D, Beebe SJ, Herlyn M. Differential expression of protein kinase C and cAMP-dependent protein kinase in normal human melanocytes and malignant melanomas. Oncogene. 1990;5:1133-1139. PMID2392322

109. Dion AS, Williams CJ, Herlyn M, Major P. Human milk fat globule membrane glycoproteins express blood group-related determinants primarily on mucin-like epithelial membrane antigens and gp70. Biochem Int. 1990;22:295-302. PMID1708665

110. Howe CC, Kath R, Mancianti ML, Herlyn M, Mueller S, Cristofalo V. Expression and structure of human SPARC transcripts: SPARC mRNA is expressed by human cells involved in extracellular matrix production and some of these cells show an unusual expression pattern. Exp Cell Res. 1990;188:185-191. PMID2335186

111. Kath R, Rodeck U, Parmiter A, Jambrosic J, Herlyn M. Growth factor independence in vitro of primary melanoma cells from advanced but not early or intermediate lesions. Cancer Therapy and Control. 1990;1:179-191.

112. Mancianti ML, Clark WH, Hayes FA, Herlyn M. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol.1990;136:817-829. PMID2327470 (PMC1877645)

113. Manni A, Wright C, Badger B, Bartholomew M, Herlyn M, Mendelsohn J, Masui H, Demers L. Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin, and progesterone. Breast Cancer Res Treat. 1990;15:73-83. PMID2322651

114. Rodeck U, Williams N, Murthy U, Herlyn M. Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem. 1990;44:69-79. PMID2250044

115. Singletary SE, Williams NN, Rodeck U, Larry L, Tucker S, Spitzer G, Herlyn M. Transforming growth factor-alpha secretion by epidermal growth factor-dependent human tumor cell lines. Anticancer Res. 1990;10:1501-1505. PMID2285223

116. Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, Rodriguez-Martinez HA, Rios-Dalenz J, Iliopoulos D, Soloway RD. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer. 1990;45:821-824. PMID2335386

117. Valyi-Nagy IT, Murphy GF, Mancianti ML, Whitaker D, Herlyn M. Phenotypes and interactions of human melanocytes and keratinocytes in an epidermal reconstruction model. Lab Invest. 1990;62:314-324. PMID2179623

118. Bröcker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin. J Invest Dermatol.1991;96:662-665. PMID1850772

13


















119. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A. 1991;88:6028-6032. PMID2068080 (PMC52015)

120. Herlyn M, Graeven U, Speicher D, Sela BA, Bennicelli JL, Kath R, Guerry DT. Characterization of tenascin secreted by human melanoma cells. Cancer Res. 1991;51:4853-4858. PMID1716515

121. Kath R, Jambrosic JA, Holland L, Rodeck U, Herlyn M. Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res. 1991;51:2205-2211. PMID2009539

122. Radrizzani M, Benedetti B, Castelli C, Longo A, Ferrara GB, Herlyn M, Parmiani G, Fossati G. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions. Int J Cancer. 1991;49:823-830. PMID1835714

123. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol. 1991;97:20-26. PMID2056188

124. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene. 1992;7:2303-2313. PMID1437152

125. Ura Y, Dion AS, Williams CJ, Olsen BD, Redfield ES, Ishida M, Herlyn M, Major PP. Quantitative dot blot analyses of blood-group-related antigens in paired normal and malignant human breast tissues. Int J Cancer. 1992;50:57-63. PMID1728614

126. Williams NN, Györfi T, Iliopoulos D, Herlyn D, Greenstein D, Linnenbach AJ, Daly JM, Jensen P, Rodeck U, Herlyn M. Growth-factor-independence and invasive properties of colorectal carcinoma cells. Int J Cancer. 1992;50:274-280. PMID1730521

127. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993;177:989-998. PMID8459226

128. Easty DJ, Ganz SE, Farr CJ, Lai C, Herlyn M, Bennett DC. Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J Invest Dermatol. 1993;101:679-684. PMID8228328

129. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A. 1993;90:393-397. PMID8380638 (PMC45668)

130. Iliopoulos D, Atkinson B, Saul SH, Herlyn M, Rodriguez-Martinez HA, West SL, Maislin G, Soloway RD, Strom BL. Differences in antigen expression between neoplastic and nonneoplastic gallbladder epithelium: an immunohistochemical study. Dig Dis Sci. 1993;38:155-160. PMID8420749

131. Juhasz I, Lazarus GS, Murphy GF, Shih IM, Herlyn M. Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients. J Clin Invest. 1993;92:2401-2407. PMID8227357 (PMC288423)

132. Juhasz I, Murphy GF, Yan HC, Herlyn M, Albelda SM. Regulation of extracellular matrix proteins and integrin cell substratum adhesion receptors on epithelium during cutaneous human wound healing in vivo. Am J Pathol. 1993;143:1458-1469. PMID7694470 (PMC1887182)

133. Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn D, Valyi-Nagy IT, Herlyn M. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol. 1993;143:528-537. PMID8342600 (PMC1887031)

134. Lazzaro B, Elder DE, Rebers A, Power L, Herlyn M, Menrad A, Johnson B. Immunophenotyping of compound and spitz nevi and vertical growth-phase melanomas using a panel of monoclonal antibodies reactive in paraffin sections. J Invest Dermatol.1993;100:313S-317S. PMID8440911

135. Mancianti ML, Györfi T, Shih IM, Valyi-Nagy I, Levengood G, Menssen HD, Halpern AC, Elder DE, Herlyn M. Growth regulation of cultured human nevus cells. J Invest Dermatol. 1993;100:281S-287S. PMID8440904

136. Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res. 1993;53:1450-1455. PMID8095183

14




















137. Salem RR, Wolf BC, Sears HF, Lavin PT, Ravikumar TS, DeCoste D, D’Emilia JC, Herlyn M, Schlom J, Gottlieb LS, Steele DG. Expression of colorectal carcinoma-associated antigens in colonic polyps. J Surg Res. 1993;55:249-255. PMID8412106

138. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med. 1993;178:1231-1246. PMID8376931

139. Valyi-Nagy IT, Hirka G, Jensen PJ, Shih IM, Juhasz I, Herlyn M. Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest. 1993;69:152-159. PMID8350597

140. Valyi-Nagy I, Shih IM, Györfi T, Greenstein D, Juhasz I, Elder DE, Herlyn M. Spontaneous and induced differentiation of human melanoma cells. Int J Cancer. 1993;54:159-165. PMID8478142

141. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer. 1993;54:693-699. PMID8514460

142. Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M, Albelda SM. Human/severe combined immunodeficient mouse chimeras: an experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. J Clin Invest. 1993;91:986-996. PMID7680673 (PMC288051)

143. Gratas C, Herlyn M, Becker D. Isolation and analysis of novel human melanocyte-specific cDNA clones. DNA Cell Biol. 1994;13:515-519. PMID8024694

144. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM. Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A. 1994;91:4499-4503. PMID8183937 (PMC43813)

145. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg SA. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol. 1994;153:1225-1237. PMID8027550

146. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer. 1994;56:853-857. PMID7509778

147. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in normal and transformed melanocytes. Melanoma Res. 1994;4:313-319. PMID7858416

148. Shih IM, Elder DE, Hsu M-Y, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol. 1994;145:837-845. PMID7943174 (PMC1887332)

149. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res. 1994;54:2514-2520. PMID8162602

150. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’-deoxycytidine. Cancer Res. 1994;54:1766-1771. PMID7511051

151. Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res. 1995;55:2528-2532. PMID7780963

152. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer. 1995;60:129-136. PMID7814145

153. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene. 1995;10:1855-1864. PMID7753561

154. Mortarini R, Gismondi A, Maggioni A, Santoni A, Herlyn M, Anichini A. Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins. Cancer Res. 1995;55:4702-4710. PMID7553652

155. Soballe PW, Maloy WL, Myrga ML, Jacob LS, Herlyn M. Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer. 1995;60:280-284. PMID7829229

15





















156. Hsu M-Y, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc. 1996;1:188-194. PMID9627715

157. Juhasz I, Simon M Jr, Herlyn M, Hunyadi J. Repopulation of Langerhans cells during wound healing in an experimental human skin/SCID mouse model. Immunol Lett. 1996;52:125-128. PMID8905406

158. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol. 1996;19:192-205. PMID8811494

159. Simon M Jr, Juhasz I, Herlyn M, Hunyadi J. Thrombospondin receptor (CD36) expression of human keratinocytes during wound healing in a SCID mouse/human skin repair model. J Dermatol. 1996;23:305-309. PMID9675818

160. Soballe PW, Montone KT, Satyamoorthy K, Nesbit M, Herlyn M. Carcinogenesis in human skin grafted to SCID mice. Cancer Res. 1996;56:757-764. PMID8631010

161. Andalib AR, Lawry J, Ali SA, Murray AK, Sisley K, Silcocks P, Herlyn M, Rees RC. Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Melanoma Res. 1997;7:32-42. PMID9067963

162. Atillasoy ES, Elenitsas R, Sauter ER, Soballe PW, Herlyn M. UVB induction of epithelial tumors in human skin using a RAG-1 mouse xenograft model. J Invest Dermatol.1997;109:704-709. PMID9406808

163. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 1997;7(suppl 2):S35-42. PMID9578514

164. Satyamoorthy K, Soballe PW, Soans F, Herlyn M. Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Cancer Res. 1997;57:1873-1876. PMID9157978

165. Shih IM, Speicher D, Hsu M-Y, Levine E, Herlyn M. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res. 1997;57:3835-3840. PMID9288796 (PMC1857834)

166. Shih IM, Hsu M-Y, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol. 1997;151:745-751. PMID9284823

167. Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res. 1997;57:3258-3263. PMID9242458

168. Atillasoy ES, Seykora JT, Soballe PW, Elenitsas R, Nesbit M, Elder DE, Montone KT, Sauter E, Herlyn M. UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol. 1998;152:1179-1186. PMID9588887 (PMC1858575)

169. Cass DL, Bullard KM, Sylvester KG, Yang EY, Sheppard D, Herlyn M, Adzick NS. Epidermal integrin expression is upregulated rapidly in human fetal wound repair. J Pediatr Surg. 1998;33:312-316. PMID9498408

170. Hsu M-Y, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 1998;153:1435-1442. PMID9811334 (PMC1853416)

171. Maul GG, Jensen DE, Ishov AM, Herlyn M, Rauscher FJ 3rd. Nuclear redistribution of BRCA1 during viral infection. Cell Growth Differ. 1998;9:743-755. PMID9751118

172. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol. 1998;13:5-9. PMID9625796

173. Rauscher FJ 3rd, Morris JF, Fredericks WJ, Lopez-Guisa J, Balakrishnan C, Jost M, Herlyn M, Rodeck U. Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms’ tumor suppressor protein. Hybridoma. 1998;17:191-198. PMID9627060

174. Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M, Herlyn M. ATF2 confers radiation resistance to human melanoma cells. Oncogene. 1998;16:523-531. PMID9484842

16





















175. Sauter ER, Klein-Szanto AJ, Atillasoy E, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn M. Ultraviolet B-induced squamous epithelial and melanocytic cell changes in a xenograft model of cancer development in human skin. Mol Carcinog. 1998;23:168-174. PMID9833777

176. Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol. 1998;11:1098-1106. PMID9831208

177. Easty DJ, Hill SP, Hsu M-Y, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer. 1999;84:494-501. PMID10502726

178. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A. 1999;96:9689-9694. PMID10449755 (PMC22271)

179. Hsu JY, Hsu M-Y, Sorger T, Herlyn M, Levine EM. Heparin/endothelial cell growth supplement regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through modulation of interleukin-1. In Vitro Cell Dev Biol Anim. 1999;35:647-654. PMID10614876

180. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, Ronai Z. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog. 1999;24:64-69. PMID10029412

181. Liechty KW, Nesbit M, Herlyn M, Radu A, Adzick NS, Crombleholme TM. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol. 1999;113:375-383. PMID10469337

182. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol. 1999;19:3916-3928. PMID10207115 (PMC84249)

183. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer. 1999;84:160-168. PMID10096249

184. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu M-Y, DeJesus E, McBrian M, Gupta AR, Eck SL, Herlyn M. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene. 1999;18:6469-6476. PMID10597249

185. Prabhu NS, Somasundaram K, Tian H, Enders GH, Satyamoorthy K, Herlyn M, El-Deiry WS. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int J Oncol. 1999;15:209-216. PMID10402229

186. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res. 1999;59:4876-4881. PMID10519399

187. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999;5:775-782. PMID10213212

188. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry DT, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, Elder DE. Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol. 1999;30:562-567. PMID10333228

189. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E, Rauscher FJ 3rd. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res. 2000;60:5803-5814. PMID11059777

190. Chandler LA, Doukas J, Gonzalez AM, Hoganson DK, Gu DL, Ma C, Nesbit M, Crombleholme TM, Herlyn M, Sosnowski BA, Pierce GF. FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther. 2000;2:153-160. PMID10947943

191. Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ 3rd. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Mol Cell Biol. 2000;20:5019-5031. PMID10866659 (PMC85952)

192. Hsu M-Y, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, Herlyn M. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515-1525. PMID10793063 (PMC1876923)

17




















193. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci. 2000;113(Pt 9):1535-1542. PMID10751145

194. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen. 2000;8:480-493. PMID11208175

195. Meier F, Nesbit M, Hsu M-Y, Martin B, Van Belle P, Elder DE, Schaumburg-Lever G, Garbe C, Walz TM, Donatien P, Crombleholme TM, Herlyn M. Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol. 2000;156:193-200. PMID10623667 (PMC1868639)

196. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter E, Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest. 2000;80:595-604. PMID10780675

197. Satyamoorthy K, Oka M, Herlyn M. An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin. Pigment Cell Res. 2000;13(suppl 8):87-93. PMID11041363

198. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 2000;11:467-474. PMID11007451

199. Sauter ER, Herlyn M, Liu SC, Litwin S, Ridge JA. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res. 2000;6:654-660. PMID10690551

200. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, Shipley J. Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer. 2000;28:121-125. PMID10738310

201. St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther. 2000;7:749-756. PMID10830722

202. Sylvester KG, Nesbit M, Radu A, Herlyn M, Adzick NS, Crombleholme TM. Adenoviral-mediated gene transfer in wound healing: acute inflammatory response in human skin in the SCID mouse model. Wound Repair Regen. 2000;8:36-44. PMID10760213

203. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res. 2001;61:8306-8316. PMID11719464

204. Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M. Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol. 2001;158:943-953. PMID11238042 (PMC1850339)

205. Doukas J, Chandler LA, Gonzalez AM, Gu D, Hoganson DK, Ma C, Nguyen T, Printz MA, Nesbit M, Herlyn M, Crombleholme TM, Aukerman SL, Sosnowski BA, Pierce GF. Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther. 2001;12:783-798. PMID11339895

206. Herlyn M, Ferrone S, Ronai Z, Finerty J, Pelroy R, Mohla S. Melanoma biology and progression. Cancer Res. 2001;61:4642-4643. PMID11389102

207. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, Furcht LT, McCarthy JB. Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem. 2001;276:18786-18794. PMID11278606

208. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene. 2001;20:8125-8135. PMID11781826

209. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61:3819-3825. PMID11325858

210. McArdle L, Rafferty M, Maelandsmo GM, Bergin O, Farr CJ, Dervan PA, O’Loughlin S, Herlyn M, Easty DJ. Protein tyrosine phosphatase genes downregulated in melanoma. J Invest Dermatol. 2001;117:1255-1260. PMID11710941

211. Nesbit M, Schaider H, Berking C, Shih DT, Hsu M-Y, McBrian M, Crombleholme TM, Elenitsas R, Buck C, Herlyn M. Alpha5 and alpha2 integrin gene transfers mimic the PDGF-B-induced

18




















transformed phenotype of fibroblasts in human skin. Lab Invest. 2001;81:1263-1274. PMID11555674

212. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001;166:6483-6490. PMID11359798

213. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 2001;61:7318-7324. PMID11585772

214. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene. 2001;20:4676-4684. PMID11498790

215. Sauter ER, Nesbit M, Tichansky D, Liu ZJ, Shirakawa T, Palazzo J, Herlyn M. Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium. Int J Cancer. 2001;92:374-381. PMID11291074

216. Sauter ER, Tichansky D, Furth EE, Herlyn M. Tumor-associated antigen expression and growth requirements predict tumorigenesis in squamous cell carcinoma. In Vitro Cell Dev Biol Anim. 2001;37:530-535. PMID11669287

217. Berking C, Takemoto R, Binder RL, Hartman SM, Ruiter DJ, Gallagher PM, Lessin SR, Herlyn M. Photocarcinogenesis in human adult skin grafts. Carcinogenesis. 2002;23:181-187. PMID11756239

218. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000. PMID12460918

219. Samadi DS, Jacobs IN, Walsh D, Bouchard S, Herlyn M, Crombleholme TM. Adenovirus-mediated ex vivo gene transfer of human vascular endothelial growth factor in a rabbit laryngotracheal reconstruction model. Ann Otol Rhinol Laryngol. 2002;111:295-301. PMID11991579

220. Satyamoorthy K, Li G, Van Belle PA, Elder DE, Herlyn M. A versatile method for the removal of melanin from ribonucleic acids in melanocytic cells. Melanoma Res. 2002;12:449-452. PMID12394186

221. Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ. 2002;13:87-93. PMID11864912

222. Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther. 2002;9:807-812. PMID12224020

223. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62:3200-3206. PMID12036934

224. Shih IM, Hsu M-Y, Oldt RJ 3rd, Herlyn M, Gearhart JD, Kurman RJ. The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. Placenta. 2002;23:706-715. PMID12398810

225. Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B, Herlyn M. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res. 2002;62:226-232. PMID11782382

226. Velazquez OC, Snyder R, Liu ZJ, Fairman RM, Herlyn M. Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. Faseb J. 2002;16:1316-1318. PMID12060671

227. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002;62:3581-3586. PMID12097256 (PMC2241738)

228. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, Rustgi AK. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation

19


















in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003;278:1824-1830. PMID12435727

229. Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M, Bennett DC, Leonard JH, Sturm RA. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol. 2003;121:1150-1159. PMID14708619

230. Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu M-Y, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, Rao JS, Baker AH, Bennet JT, Crombleholme TM, Velazquez O, Karmacharya J, Margolis DJ, Wilson JM, Detmar M, Skobe M, Robbins PD, Buck C, Herlyn M. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol. 2003;120:683-692. PMID12648235

231. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198-5202. PMID14500344

232. Hirst CJ, Herlyn M, Cattini PA, Kardami E. High levels of CUG-initiated FGF-2 expression cause chromatin compaction, decreased cardiomyocyte mitosis, and cell death. Mol Cell Biochem. 2003;246:111-116. PMID12841351

233. Kalabis J, Patterson MJ, Enders GH, Marian B, Iozzo RV, Rogler G, Gimotty PA, Herlyn M. Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. Faseb J. 2003;17:1115-1117. PMID12692084

234. Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene. 2003;22:6891-6899. PMID14534536

235. Liu ZJ, SnyderR, Soma A, Shirakawa T, Ziober BL, Fairman RM, Herlyn M, Velazquez OC. VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. Faseb J. 2003;17:1931-1933. PMID14519669

236. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003;23:14-25. PMID12482957 (PMC140667)

237. Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Moller H, Maczey E, Rassner G, Herlyn M, Garbe C. Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. Exp Dermatol. 2003;12:296-306. PMID12823444

238. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003;63:756-759. PMID12591721

239. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K, Herlyn M. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer. 2003;103:335-343. PMID12471616

240. Song JH, Song DK, Herlyn M, Petruk KC, Hao C. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res. 2003;9:4255-4266. PMID14519653

241. Zhang H, Satyamoorthy K, Herlyn M, Rosdahl I. All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells—a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis. 2003;24:185-191. PMID12584166

242. Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene. 2004;23:5252-5256. PMID15229656

243. Berking C, Takemoto R, Satyamoorthy K, Shirakawa T, Eskandarpour M, Hansson J, VanBelle PA, Elder DE, Herlyn M. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res. 2004;64:807-811. PMID14871803

20


















244. Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet. 2004;41:270-272. PMID15060100 (PMC1735752)

245. Keswani SG, Katz AB, Lim FY, Zoltick P, Radu A, Alaee D, Herlyn M, Crombleholme TM. Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds. Wound Repair Regen. 2004;12:497-504. PMID15453831

246. Kim, SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem. 2004;279:40044-40052. PMID15226295

247. Kim JW, Wong CW, Goldsmith JD, Song C, Fu W, Allion MB, Herlyn M, Al-Mehdi AB, Muschel RJ. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells. Cancer Lett. 2004;213:203-212. PMID15327836

248. Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. Exp Cell Res. 2004;297:142-151; Corrigendum 2005;305:436. PMID15194432

249. Margolis DJ, Cromblehome T, Herlyn M, Cross P, Weinberg L, Filip J, Propert K. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A. Hum Gene Ther. 2004;15:1003-1019. PMID15585116

250. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart GW. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol. 2004;122:1293-1301. PMID15140234

251. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004;64:4394-4399. PMID15231645

252. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, Liu ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest. 2005;115:3166-3176. PMID16239965 (PMC1257536)

253. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328-9337. PMID16230395

254. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-913. PMID15829965

255. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol. 2005;166:823-830. PMID15743794 (PMC1602342)

256. McArdle L, Rafferty MM, Satyamoorthy K, Maelandsmo GM, Dervan PA, Herlyn M, Easty DJ. Microarray analysis of phosphatase gene expression in human melanoma. Br J Dermatol. 2005;152:925-930. PMID15888148

257. Price KL, Herlyn M, Dent CL, Gewert DR, Linge C. The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Res. 2005;15:91-98. PMID15846141

258. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol. 2005;166:1541-1554. PMID15855653 (PMC1606406)

259. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol. 2005;174:5856-5863. PMID15843590

260. Fang D, Leishear K, Nguyen TK, Finko R, Cai K, Fukunaga M, Li L, Brafford PA, Kulp AN, Xu X, Smalley KS, Herlyn M. Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells. 2006;24:1668-1677. PMID16574754

261. Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MPAK and PI3K/Akt pathways and requires MAML1. Faseb J. 2006;20:1009-1011. PMID16571776

21



















262. Liu Z-J, Xiao M, Balint K, Smalley KSM, Brafford P, Qiu E, Pinnix CC, Li X, Herlyn M. Notch1 signaling promotes primary melanoma progression by activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-kKnase-Akt pathways and upregulating N-cadherin expression. Cancer Res. 2006;66:4182-4190. PMID16618740

263. Oka M, Norose K, Matsushima K, Nishigori C, Herlyn M. Overexpression of IL-8 in the cornea induces ulcer formation in the SCID mouse. Br J Ophthalmol. 2006;90:612-615. PMID16418304 (PMC1857070)

264. Oka M, Nishigori C, Kageshita T, Hsu M-Y, Penmatcha S, Herlyn M. Expression of PKC isoforms in human melanocytic cells in situ. J Dermatol Sci. 2006;41:157-161. PMID16406501

265. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molec Cancer Therapy. 2006;5:1136-1144. PMID16731745

266. Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, Herlyn M, Xu X. Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol. 2006;168:1879-1988. PMID16723703 PMC(1606635)

267. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pig Cell Res. 2006;19:290-302. PMID16827748

268. Spoettl T, Hausmann M, Herlyn M, Gunckel M, Falk W, Herfarth H, Schoelmerich J, Rogler G. Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. Clin Exp Immunol. 2006;145:190-199. PMID16792690 (PMC1942009)

269. Spoettl T, Hausmann M, Gunckel M, Herfarth H, Herlyn M, Schoelmerich J, Rogler G. A new organotypic model to study cell interactions in the intestinal mucosa. Eur J Gastroenterol Hepatol. 2006;18:901-909. PMID16825910

270. Liu J, Kumar SKG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY. Oncogenic BRAF regulates ß-Trep expression and NF-ĸB activity in human melanoma cells. Oncogene. 2007;26:1954-1958. PMID170001349 (PMC1903341)

271. Dicker DT, Lerner J, Van Belle P, Barth SF, Guerry D 4th, Herlyn M, Elder DE, El-Deiry WS. Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther. 2006;5:1033-1038. PMID16931902

272. Andl CD, Fargnoli BB, Okawa T, Bowser M, Takaoka M, Nakagawa H, Klein-Szanto A, Hua X, Herlyn M, Rustgi AK. Coordinated functions of E-cadherin and TGFß receptor II in vitro and in vivo. Cancer Res. 2006;66:9878-9885. PMID17047049 (PMC2996096)

273. Fukunaga-Kalabis M, Martinez G, Liu Z-J, Kalabis J, Mrass P, Weninger W, Firth SM, Planque N, Perbal B, Herlyn M. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol. 2006;175:563-569. PMID17101694 (PMC2064593)

274. Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl C, Kim S-H, Klein-Szanto A, Diehl JA, Herlyn M, El-Deiry W, Rustgi AK. Akt induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene. 2006;26:2353-2364. PMID17043653 (PMC2996093)

275. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang S-Y, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KAM, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006;66:11100-11105. PMID17145850

276. Smalley KSM, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 2007;67:209-217. PMID17210701

277. Lioni M, Brafford P, Andl A, Rustgi A, El-Deiry W, Herlyn M, Smalley KSM. Dysregulation of Claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol. 2007;170:709-721. PMID17255337 (PMC1851859)

22



http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16618740


278. Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Brit J Cancer. 2007;96:445-449. PMID17210701 (PMC2360037)

279. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, Schitteck B. Combining targeting MAPK and AKT signaling pathways is a promising strategy for melanoma therapy. Br J Derm. 2007;156:1204-1213. PMID17388918

280. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 2007;67:3177-3184. PMID17409425

281. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nature Genet. 2007;39:347-351. PMID17293865; Corrigendum 2007;39:567. PMID17392811

282. Seidl H, Richtig E, Tilz H, Stefan M, Schmidbauer U, Asslaber M, Zatloukal K, Herlyn M, Schaider H. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol. 2007;38:768-780. PMID17306330

283. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z. Re-wired ERK-JNK signaling pathways in melanoma. Cancer Cell. 2007;11:447-460. PMID17482134 (PMC1978100)

284. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Molec Diagn. 2007;9:464-471. PMID17690212 (PMC1975103)

285. Kumar KGS, Liu J, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY. Raf inhibitor stabilizes receptor for type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther. 2007;6:1437-1441. PMID17873516 (PMC2254442)

286. Wenke AK, Kjellman C, Lundgren-Akerlund E, Uhlmann C, Haass NK, Herlyn M, Bosserhoff AK. Expression of integrin alpha 10 is induced in melanoma. Cell Oncol. 2007;29:373-386. PMID17726260

287. Lin WM, Baker AC, Beroukhim R, Winkler W, Feng W, Marmion J, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff GM, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68:664-673. PMID18245465

288. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl C, Johnstone CN, Klein-Szanto AI, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay between EGFR, hTERT activation and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induce tumor development, invasion and differentiation. Genes Devel. 2007;21:2788-2803. PMID17974918 (PMC2045132)

289. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu Z-J, Balint K, Juhasz I, Elder DE, Perbal B, Herlyn M. Loss of CCN3 expression as a potential mechanism for melanoma progression. Oncogene. 2007;27:2552-2558. PMID17968313 (PMC N/A)

290. Han M-J, Herlyn M, Fisher AB, Speicher DW. Microscale solution IEF combined with 2-D DIGE substantially enhances analysis depth of complex proteomes such as mammalian cell and tissue extracts. Electrophoresis. 2008;29:695-705. PMID18186533 (PMC N/A)

291. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KSM. The MEK inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008;14:230-239. PMID18172275 (PMC N/A)

23


292. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gilette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KSM, Fong D, Zhu Y-L, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Liu C, Settachatgul C, Shellooe R, Cantwell J, Kim S-H, Schlessinger J, Zhang KYJ, West B, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G. Discovery of a novel selective inhibitor of oncogenic B-Raf kinase with potent anti-melanoma activity. Proc Nat Acad Sc U S A. 2008;26:3041-3049. PMID18287029 (PMC2268581)

293. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin A, Nuciforo P, Cavallaro U. The differential role of L1 in normal and transformed ovarian surface epithelium. Cancer Res.2008;68:1110-1118. PMID18281486 (PMC N/A)

294. Gordon A, Kozin ED, Keswani SG, Vaikunth SS, Katz AB, Zoltick PW, Favata M, Radu AP, Soslowsky LJ, Herlyn M, Crombleholme TM. Permissive environment in postnatal wounds by adenoviral-mediated overexpression of the anti-inflammatroy cytokine interleukin-10 prevents scar formation. Wound Repair Regen. 2008;16:70-79. PMID18086289 (PMC N/A)

295. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M. Cancer testis antigens in human melanoma stem cells: expression, distribution and methylation status. J Cell Physiol. 2008;215:287-291. PMID1802582 (PMC N/A)

296. Noma K, Smalley KSM, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa H, Herlyn M. An essential role for stromal fibroblasts and transformating growth factors (TGF)-ß in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterol. 2008;134:1981-1993. PMID18439605 (PMC2562524)

297. Maksimoska J, Williams DS, Atilla-Gokcumen GE, Smalley KSM, Carroll PJ, Webster RD, Filippakopoulos P, Knapp S, Herlyn M, Meggers E. Isostructural ruthenium and osmium complexes display highly similar bioactivities. Chemistry. 2008;14:4816-4822. PMID18425743 (PMC2753370)

298. Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Duesberg NS, Houghton A, Frankel AE. Cytotoxicity of the engineered matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molec Cancer Therap. 2008;8:1218-1226. PMID18483309 (PMC2757055)

299. Kalabis J, Li G, Fukunaga-Kalabis M, Rustgi A, Herlyn M. Endothelin-3 stimulates survival of goblet cells in organotypic cultures of human colonic epithelium. Am J Physiol - GI Liver Physiol. 2008;295:G1182-1189. PMID18832450 (PMC2604801)

300. Smalley KSM, Contractor R, Nguyen TK, Xiao M, Medinca A, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Identification of a novel sub-group of melanomas with kit/cyclin-dependent kinase-4 overexpression. Cancer Res. 2008;68:5743-5752. PMID18632627 (PMC2615688)

301. Xie P, Williams DS, Atilla Gokumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers E, Marmorstein R. Structure-based design of an organoruthenium phosphotidyl-inositol-3-kinase inhibitor revieals a switch governing lipid kinase potency and selectivity. ACS Chem Biol. 2008;3:305-316. PMID18484710 (PMC3618672)

302. Smalley KSM, Lioni M, Palma MD, Xiao M, Desai B, Eghazi S, Hansson J, Hong W, King AJ, Flaherty KT, Herlyn M, Nathanson KL. Cyclin D1 mediates BRAF inhibitor resistance in a sub-set of BRAF-V600E mutated melanomas. Molec Can Ther. 2008;7:2876-2883. PMID18790768 (PMC2651569)

303. Lioni M, Noma K, Snyder A, Rustgi A, Diehl JA, Herlyn M, Smalley K. Bortezomib-induced cellular stress via the p38 MAPK pathway leads to a DNA damage response and apoptosis in esophageal squamous cell carcinoma cells. Molec Cancer Ther. 2008;7:2866-2875. PMID18790767 (PMC2903039)

304. Harada H, Nakagawa H, Takaoka M, Lee J, Herlyn J, Diehl JA, Rustgi AK. Cleavage of MCM2 licensing proteins fosters senescence in human keratinocytes. Cell Cycle. 2008;7:3534-3538. PMID19001876 (PMC2736109)

305. Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB, Figueiredo JL, Mahmood U, Diehl JA, Herlyn M, Rustgi AK. A sub-population of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest. 2008;118:3860-3869. PMID19005570 (PMC2579884)

24


306. Smalley KSM, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Nathanson KL, Herlyn M. CRAF inhibition induces Bcl-2 dependent apoptosis in melanomas with non V600E BRAF mutations. Oncogene. 2009;28:85-94. PMID18794803 (PMC2898184)

307. Greshok J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, Zaks TZ. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma derived cell lines. Genes, Chromosomes, Cancer. 2009;48:419-428. PMID19226609 (PMC2885833)

308. Yu H, McDaid R, Lee J, Possik P, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Plama M, Herlyn M, Xu X. Role of BRAF mutation and p53 inactivation during transformation of a sub-population of primary human melanocytes. Am J Pathol. 2009;174:2367-2377. PMID19389934 (PMC2684200)

309. Pinnix CC, Lee JT, Liu Z-J, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WE, Capobianco AJ, Herlyn M. Active Notch1 protein confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69:5312-5320. PMID19549918 (PMC2755513)

310. Degenhardt Y, Huang J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B. Distinct MHC gene expression patterns during progression of melanoma. Genes, Chromosomes, Cancer. 2010;49:144-154. PMID19907984 (PMC2796267)

311. Katz AB, Keswani SG, Habli M, Lim FY, Zoltick PW, Midrio P, Kozin ED, Herlyn M, Crombleholme TM. Placental gene transfer: transgene screening in mice for trophic effects on the placenta. Am J Obstet Gynocol. 2009;201:499.e1-8. PMID19716119. (PMC2885953)

312. Li L, Fukunaga-Kalabis M, Yu H, Xu X, Kong J, Lee JT, Herlyn M. Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci. 2010;123:853-860. PMID20159965 (PMC2831759)

313. Ohashi S, Natsuizaka M, Wong GS, Michaylira CZ, Grugan KD, Nakagawa N, Klein-Szanto AJ, Herlyn M, Diehl JA, Rustgi AK, Nakagawa H. EGFR and mutant p53 expand esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res. 2010;70:4174-4184. PMID20424117 (PMC3007622)

314. Basu D, Nguyen T-T, Montone KT, Zhang G, Wang L-P, Diehl JA, Rustgi AK, Lee JT, Weinstein GS, Herlyn M. Mesenchymal sub-populations within squamous cell carcinomas exhibiting chemoresistance and phenotypic plasticity. Oncogene. 2010;29:4170-4182. PMID20498638 (PMC3039880)

315. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583-594. PMID204782552 (PMC2882693).

316. Natsuizaka M, Ohashi S, Wong G, Ahmadi A, Kalman R, Budo D, Klein-Szanto A, Herlyn M, Diehl A, Nakagawa H. Insulin-like growth factor binding protein-3 promotes transforming growth factor-ß1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis. 2010;31:1344-1353. PMID20513670 (PMC2915630)

317. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P, Rustgi AK. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res. 2010;70:5281-5291. PMID20516120 (PMC3274349)

318. Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han M, Nakagawa H, Rustgi AK. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal cell carcinoma invasion. Proc Natl Acad Sci U S A. 2010;107:11026-11031. PMID20534479 (PMC2890722)

319. Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, Klein-Szanto AJ, Herlyn M, Diehl JA, Kathz JP, Pear WS, Seykora JT, Nakagawa H. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterol. 2010;139:2113-2123. PMID20801121 (PMC2997138)

25


320. Fukunaga-Kalabis M, Martinez G, Nguyen T-TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M. Tenascin promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010;29:6115-6124. PMID2072997 (PMC2991494)

321. Aggarwal P, Vaites LP, Kim JK, Mellert H, Nakagawa H, Herlyn M, Rustgi A, McMahon SB, Diehl JA. Nuclear Cyclin D1/CDK4 minase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010;18:329-340. PMID20951943 (PMC2957477)

322. Lee J, Li L, Brafford P, Sproesser K, Haass N, Smalley K, van den Eijnden M, Halloran M, Tsai J, Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibitrs V600E-positive melanomas. Pig Cell Mel Res. 2010;23:820-827. PMID20973932 (NIHMS452487, PMC in Progress)

323. Han M-J, Wang H, Beer LA, Tang H-Y, Herlyn M, Speicher D. A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics. 2010;10:4450-4462. PMID21082759 (PMC3070844)

324. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K, Pushparajan A, Hayden JE, Dahlman K, Laquerre S., McArthur G, Sosman J, Nathanson KL, Herlyn M. Acquired resistance to BRAF inhibitors mediated by an A/B/C RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-695. PMID21156289 (PMC3026446)

325. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E, Leonard JH, Herlyn M, Sturm RA. Inverse expression of BRN2 and MITF transcription factors in melanoma spheres and tumor xenografts regulate the NOTCH pathway. Oncogene. 2011;30:3036-3048. PMID21358674 (PMC3591523)

326. Zabierowski SE, Baubet V, Himes B, Li L, Fukunaga-Kalabis M, Patel S, McDaid R, Guerra M, Gimotty P, Dahmane N, Herlyn M. Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. Stem Cells. 2011;1752-62. PMID21948558 (PMC3615703)

327. Magnitsky S, Roesch A, Herlyn M, Glickson JD. In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magn Reson Med. 2011;66:1362-1372. PMID21523820 (PMC3145816)

328. Basu D, Montone KT, Wang L-P, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS, Herlyn M. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle. 2011;10:2008-2016. PMID21558812 (PMC3154419)

329. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp. 2011;54:e2937. PMID21847077 (PMC3159964)

330. Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA, Nakagawa M, Darling DS, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT competent cells that express the ZEB transcription factors. Cancer Res. 2011;71:6636-6847. PMID21890822 (PMC3206139)

331. Blanck S, Cruchter T, Vultur A, Riedel R, Harms K, Herlyn M, Meggers E. Organometallic pyridylnaphthalimide complexes as protein kinase inhibitors. Organometallics. 2011;30:4598-4606. PMID21918590 (PMC3170819)

332. Flach EH, Rebecca VW, Herlyn M, Smalley KSM, Anderson ARA. Fibroblasts contribute to melanoma tumor growth and drug resistance. Molecular Pharm. 2011;8:2039-2049. PMID22067046 (PMC3235959)

333. Feng Y, Barile E, De SK, Stebbins JL, Cortez A, Aza-Blanc P, Villanueva J, Herlyn M, Krajewski S, Melecchia M, Ronai ZA, Chiang GG. Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-kB pathways. Pigm Cell Mel Res. 2011;24:703-713. PMID21592316 (PMC3076536)

334. Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nature Protocols. 2012;7:235-246. PMID22240585 (PMC3505594)

26

http://www.ncbi.nlm.nih.gov/pubmed?term=Herlyn%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Dahmane%20N%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Guerra%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=McDaid%20R%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Patel%20S%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Fukunaga-Kalabis%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Li%20L%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Himes%20B%5BAuthor%5D&cauthor=true&cauthor_uid=21948558

http://www.ncbi.nlm.nih.gov/pubmed?term=Baubet%20V%5BAuthor%5D&cauthor=true&cauthor_uid=21948558


335. Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfisterhammer K, Gschaider M, Lai CY, Hsu M-Y, Herlyn M, Stingl G, Wagner SN. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 2012;20:1056-1062. PMID22354376 (PMC3345981)

336. Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biol Open. 2012;1:516-526. PMID23213444 (PMC3509444)

337. Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigm Cell Mel Res. 2012;25:493-505. PMID22498258 (PMC3615702)

338. Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler JD, Marmorstein R. Identification of a novel family of BRAFV600E inhibitors. J Med Chem. 2012;55:5220-5230. PMID22537109 (PMC3383862)

339. Furney SJ, Turajlic S, Fenwick K, Lambros MB, Mackay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R. Genomic characterisation of acral melanoma cell lines. Pigment Cell Mel Res. 2012;25:488-492. PMID22578220 (PMC – N/A)

340. John JK, Paraiso KHT, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KSM. GSK3ß inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol. 2012;132:2818-2827. PMID22810307 (PMC3479306)

341. Naganuma S, Whelan KA, Natsuizaka S, Kinugasa H, Chang S, Subramanian H, Rhoades B, Ohashi S, Itoh H, Herlyn M, Diehl JA, Gimotty PA, Klein-Szanto AJ, Nakagawa H. Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma. Am J Cancer Res. 2012;2:459-475. PMID22860235 (PMC3410579)

342. Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, Puré E. Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med Genomics. 2012;5:39. PMID22954256 (PMC3505468)

343. Chae YC, Caino MC, Lisanti S, Gosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90. Cancer Cell. 2012;22:331-344. PMID22975376 (PMC3615709)

344. Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C. Development of a novel class of B-RAF (V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem. 2012;10:7402-7417. PMID22875039 (PMC3427755)

345. Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live melanoma samples using a novel automated platform. PLos One. 2012;7:e52760. PMID23285177 (PMC3532357)

346. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res. 2013;11:219-229. PMID23303345 (PMC3606282)

347. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M. The novel SMAC inhibitor birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013;19:1784-1794. PMID23403634 (PMC3618595)

348. Kastl A, Dieckman S, Wähler K, Völker T, Kastl L, Shannan B, Harms K, Ocker M, Parak W, Herlyn M, Meggers E. Rhenium complexes with visible-light-induced anticancer activity. Organometallic Med Chem. 2013;8:924-927. PMID23568508 (PMC3665699)

349. Desai BM, Villanueva J, Nguyen T-TK, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KSM, Herlyn M. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One. 2013;8(3):e59588. PMID23527225 (PMC3601112)

350. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang 27


R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 2013;3:1-4. PMID23562156 (PMC3840499 [Available on 2014/4/25]; NIHMS466586)

351. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian B, Vogt T, Herlyn M. Overcoming intrinsic multi-drug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013;23:811-825. PMID23764003 (PMC3810180 [Available on 2014/6/10])

352. Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013;73:4383-4394. PMID23651636

353. Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, Faranda A, Fakharzadeh SS, Herlyn M, Johnson ATC, Preti G. Volatile biomarkers from human melanoma cells. J Chromatography B Analyt Technol Biomed Life Sci. 2013;931:90-96. PMID23770738

354. Villanueva J, Infante J, Krepler C, Reyes-Uribe P, Samanta M, Chen H-Y, Li B, Swoboda R, Wilson M, Vultur A, Fukunaga-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini D, Gilmer T, Martin A-M, Marmorstein R, Schultz D, Speicher D, Karakousis G, Xu W, Amaravadi R, Xu X, Schuchter L, Herlyn M, Nathanson K. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Reports. 2013;4:1090-1099. PMID24055054

355. Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M. EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. Molec Cancer Ther. 2013;12:2176-2186. PMID23939378 (PMC3796003 [Available on 2014/10/1])

356. Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl N, Barbash O, Schuchter LM, Amaravadi RK, Xu X, Herlyn M, Nathanson KL, Diehl JA. The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol. 2013;33:4422-4433. PMID24019069

357. Rasänen K, Speicher K, Valiga A, Tang H-Y, Zhang G, Perego M, Somasundaram R, Li L, Sriwasdi S, Klein-Szanto A, Basu D, Rustgi AK, Speicher DW, Herlyn M. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Molec Cell Proteomics. 2013;12(12):3778-92. PMID24037664

358. Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T, Xu X, Hwang W-T, Lieu M, Belser E, Liu R, Somasundaram R, Herlyn M, Kaufman RE. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. J Invest Dermatol. 2014; 134:1108-1118. PMID24157461

359. Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, Herlyn M, Gimotty P, Nakagawa H, Rustgi AK. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophagus tumor microenvironment. Oncogenesis. 2013;2:e59. PMID23917221 (PMC3759121)

360. O'Connell M, Marchbank K, Webster M, Valiga A, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli T, Indig FE, Flaherty K, Wargo J, Frederick DT, Cooper Z, Nair S, Amaravadi R, Schuchter L, Karakousis G, Xu W, Xu X, Weeraratna AT. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery. 2013;3(12):1378-93. PMID24104062

361. Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M, Mauviel A. Pro-invasive activity of the hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2014;134:123-132. PMID23897276

362. Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Li L, Gimotty P, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 2014; 33: 1850-1861. PMID23624919 (PMC3769503)

363. Ma X-H, Pioa S-F, Dey S, Mcafee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress induced autophagy overcomes resistance to

28


BRAF inhibition in melanoma. J Clin Invest. 2014;124:1406-1417. PMID24569374364. Hayashizaki Y et al. FANTOM consortium and the RIKEN PMI and CLST (DGT) (...Herlyn M...).

Nature. 2014;507:462-470. PMID 24670764365. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X,

Schmidl C, Suzuki T, Ntini E, Arner E, Valen E, Li K, Schwarzfischer L, Glatz D, Raithel J, Lilje B, Rapin N, Bagger FO, Jørgensen M, Andersen PR, Bertin N, Rackham O, Burroughs AM, Baillie JK, Ishizu Y, Shimizu Y, Furuhata E, Maeda S, Negishi Y, Mungall CJ, Meehan TF, Lassmann T, Itoh M, Kawaji H, Kondo N, Kawai J, Lennartsson A, Daub CO, Heutink P, Hume DA, Jensen TH, Suzuki H, Hayashizaki Y, Müller F; FANTOM Consortium (...Herlyn M...), Forrest AR, Carninci P, Rehli M, Sandelin A. An atlas of active enhancers across human cell types and tissues. Nature. 2014 Mar 27;507(7493):455-61. PMID24670763

366. Morikawa H, Ohkura N, Vandenbon A, Itoh M, Nagao-Sato S, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest AR, Standley, DM, Date H, Sakaguchi S; FANTOM Consortium (...Herlyn M...). Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation. Proc Natl Acad Sci USA. 2014;111:5289-5294. PMID24706905

367. Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KL, Rauscher FJ 3rd. LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Res. 2014;74(5):1390-1403. PMID24590809

368. Arner E , Forrest AR, Ehrlund A, Mejhert N, Itoh M, Kawaji H, Lassmann T, Laurencikiene J, Rydén M, Arner P, FANTOM Consortium (...Herlyn M...). Ceruloplasmin is a novel adipokine which is overexpressed in adipose tissue of obese subjects and in obesity-associated cancer cells. PLoS One. 2014;9(3):e80274. PMID24676332

369. Hasegawa Y, Tang D, Takahashi N, Hayashizah Y, Forrest AR, FANTOM Consortium (…Herlyn M…), Suzuki H. CCL2 enhances pluripotency of human induced pluripotent stem cells by activating hypoxia related genes. Sci Rep. 2014;4:5228. PMID24957798

370. Yang R, Zhend Y, Li L, Liu S, Spata M, Wei Z, Nace A, Herlyn M, Cui R, Guo W, Cotsarelis G, Xu X. Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors. Nat Comm. 2014;5:5807. PMID25510211

371. Cierlitza M, Chauvistre H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, Vogt T, Roesch A. Mitochondiral oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma subpopulations. Exp Dermatol. 2015;24:155-157. PMID25453510

372. Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad BE, Hass N, Soyer P, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H. A stress-induced early innate response causes multi-drug tolerance in melanoma. Oncogene. [Epub ahead of print]. PMID25619837

373. Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy. 2015;11:60-74. PMID25484078

374. Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O’Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG, Kossenov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT. Wnt5a promotes and adaptive, senescence-like stress stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res. 2015;28:184-195. PMID25407936

375. Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drablos F, Lennartsson, A, Rönnerblad M, Hrydziuszko O, Vitezic M, Freeman TC, Alhendi A, Arner A, Axton R, Baillie JK, Beckhouse A, Bodega B, Briggs J, Brombacher F, Davis M, Detmar M, Ehrlund A, Endoh M, Eslami A, Fagiolini M, Fairbairn L, Faulkner GJ, Ferrai C, Fisher ME, Forrester L, Goldowitz D, Guler R, Ha T, Hara M, Herlyn M, Ikawa T, Kai C, Kawamoto H, Khachigian L, Klinken PS, Kojima S, Koseki H, Klein S, Mejhert N, Miyaguchi K, Mizuno Y, Morimoto M, Morris KJ, Mummery C, Nakachi Y, Ogishima S, Okada-Hatakeyama M, Okazaki Y, Orlando Y, Ovchinnikov D, Passier R, Patrikakis M, Pombo A, Qin XY, Roy S, Sato H, Savvi S, Saxena A, Schwegmann A, Sugiyama D, Swoboda R, Tanaka R, Tomoiu A, Winteringham LN, Wolvetang E, Yanagi-Mizuochi C,

29

http://www.ncbi.nlm.nih.gov/pubmed?term=Arner%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Ryd%C3%A9n%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Laurencikiene%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Lassmann%20T%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Kawaji%20H%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Itoh%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Mejhert%20N%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Ehrlund%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Forrest%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed?term=Arner%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24676332

http://www.ncbi.nlm.nih.gov/pubmed/24590809



http://www.ncbi.nlm.nih.gov/pubmed?term=Forrest%20AR



Yoneda M, Zabierowski S, Zhang P, Abugessaisa I, Bertin N, Diehl AD, Fukuda S, Furuno M, Harshbarger J, Hasegawa A, Hori F, Ishikawa-Kato S, Ishizu Y, Itoh M, Kawashima T, Kojima M, Kondo N, Lizio M, Meehan TF, Mungall CJ, Murata M, Nishiyori-Sueki H, Sahin S, Sato-Nagao S, Severin J, de Hoon MJL, Kawai J, Kasukawa T, Lassmann T, Suzuki H, Kawaji H, Summers KM, Wells C, Hume DA, Forrest ARR, Sandelin A, Carninci P, Hayashizaki Y. Gene regulation; transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. 2015 Feb 27;347(6225):1010-4. PMID25678556

376. Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn, M, Kaufman, R. BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth. Cancer Res. 2015 [Epub ahead of print]. PMID25617424

377. Joshi S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, Holmen SL, Otte M, Herlyn M, Waldhoer M, Schaider H. Galpha(13) mediates human cytomegalovirus-encoded chemokine receptor US28 induced cell death in melanoma. Int J Cancer. Epub ahead of print, 6 Mar 2015. PMID25754407

378. Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdiev A, Webster MR, Oka M, Weeraratna AT, Herlyn M. UV-induced Wnt7a in the human skin microenvironment specifies the fate of neural crest-like cells via suppression of Notch. J Invest Dermatol. Epub ahead of print, 23 Feb 2015. PMID25705850

Research Publications, Peer-Reviewed Reviews 1. Koprowski H, Herlyn M. Human tumor antigens. In: Wahren B, ed. Molecular Biology of Tumor

Cells. Raven Press; 1985:123-138.2. Ross AH, Herlyn M, Maul GG, Koprowski H, Bothwell M, Chao M, Pleasure D, Sonnenfeld KH.

The nerve growth factor receptor in normal and transformed neural crest cells. Ann N Y Acad Sci. 1986;486:115-123. v3032054

3. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H. Biology of tumor progression in human melanocytes. Lab Invest. 1987;56:461-474. PMID3553733

4. Herlyn M, Rodeck U, Koprowski H. Shedding of human tumor-associated antigens in vitro and in vivo. Adv Cancer Res. 1987;49:189-221. PMID3314394

5. Herlyn M, Clark WHJ. Human melanoma: biology of tumor progression. The Melanoma Letter. 1987;5:3-4.

6. Rodeck U, Menssen HD, Herlyn M. Growth factors in the pathogenesis of malignant diseases. Dtsch Med Wochenschr. 1988;113:904-906. PMID3286186

7. Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol. 1988;6:283-308. PMID3289568

8. Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages of tumor progression. Cancer Treat Res. 1988;43:3-16. PMID2908575

9. Kath R, Herlyn M. Molecular biology of tumor antigens. Curr Opin Immunol. 1989;1:863-866. PMID2679733

10. Williams NN, Daly JM, Herlyn M. Primary colorectal carcinoma cell lines contain subpopulations with invasive properties. Surgical Forum. 1989;40:400-403.

11. Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumor antigens. J Natl Cancer Inst. 1990;82:1883-1889. PMID2250310

12. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev. 1990;9:101-112. PMID2253310

13. Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U. Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv Cancer Res. 1990;54:213-234. PMID2404378

14. Valyi-Nagy I, Herlyn M. Melanocyte maturation and differentiation. Lab Invest. 1990;63:276-277. 15. Herlyn M, Malkowicz SB. Regulatory pathways in tumor growth and invasion. Lab Invest.

1991;65:262-271. PMID1890806 16. Rodeck U, Becker D, Herlyn M. Basic fibroblast growth factor in human melanoma. Cancer Cells.

1991;3:308-311. PMID1931440

30














17. Rodeck U, Herlyn M. Growth factors in melanoma. Cancer Metastasis Rev. 1991;10:89-101. PMID1873858

18. Herlyn D, Linnenbach A, Koprowski H, Herlyn M. Epitope- and antigen-specific cancer vaccines. Int Rev Immunol. 1991;7:245-257. PMID1779173

19. Valyi-Nagy IT, Herlyn M. Regulation of growth and phenotype of normal human melanocytes in culture. Cancer Treat Res. 1991;54:85-101. PMID1673861

20. Herlyn D, Adachi K, Koprowski H, Herlyn M. Experimental model of human melanoma metastases. Cancer Treat Res. 1991;54:105-118. PMID1673854

21. Graeven U, Rodeck U, Weinmann R, Herlyn M. Stable transfection of human malignant melanoma cells with basic fibroblast growth factor antisense cDNA. Ann N Y Acad Sci. 1992;660:293-294. PMID1340139

22. Graeven U, Herlyn M. In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression. J Immunother. 1992;12:199-202. PMID1445812

23. Menrad A, Herlyn M. Tumor progression, biology, and host response in melanoma. Curr Opin Oncol. 1992;4:351-356. PMID1591308

24. Elder DE, Herlyn M. Antigens associated with tumor progression in melanocytic neoplasia. Pigment Cell Res. 1992;3(suppl 2):136-143. PMID1409415

25. Shih IM, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol. 1993;100:196S-203S. PMID8381840

26. Soballe PW, Herlyn M. Cellular pathways leading to melanoma differentiation: therapeutic implications. Melanoma Res. 1994;4:213-223. PMID7950357

27. Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res. 1994;7:81-88. PMID8066024

28. Nesbit M, Herlyn M. Adhesion receptors in human melanoma progression. Invasion Metastasis. 1994;14:131-146. PMID7657508

29. Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo. 1994;8:113-123. PMID7519892

30. Soballe PW, Daly JM, Herlyn M. Human carcinogenesis in SCID/human chimeras: a cutaneous model. ACS Surgical Forum. 1994;65:559-561.

31. Herlyn M, Satyamoorthy K. Activated ras: yet another player in melanoma? Am J Pathol. 1996;149:739-744. PMID8780377 (PMC1865164)

32. Satyamoorthy K, Nesbit M, Hsu M-Y, Herlyn M. Utility of adenoviruses as gene expression modules in melanoma. Biomedical and Health Res. 1996;12:71-77.

33. Hsu M-Y, Herlyn M. Cultivation of normal human epidermal melanocytes. In: Jones GE, ed. Methods in Molecular Medicine: Human Cell Culture Protocols. Totowa, NJ: Humana Press; 1996:9-20.

34. Smalley KSM, Herlyn M. Towards the targeted therapy of melanoma. Mini-Rev Med Chem. 2006;6:109-120.

35. Satyamoorthy K, Herlyn M. Melanoma: molecular and cellular abnormalities. In: Bertino JR, ed. Encyclopedia of Cancer II. San Diego, CA: Academic Press; 1997:1042-1050.

36. Sauter ER, Herlyn M. Molecular biology of human melanoma development and progression. Mol Carcinog. 1998;23:132-143. PMID9833774

37. Meier F, Satyamoorthy K, Nesbit M, Hsu M-Y, Schittek B, Garbe C, Herlyn M. Molecular events in melanoma development and progression. Front Biosci. 1998;3:D1005-1010. PMID9740553

38. Kamb A, Herlyn M. Malignant melanoma. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York, NY: McGraw-Hill Co.; 1998:507-518.

39. Nesbit M, Seatluri V, Herlyn M. Biology of melanocytes and melanoma. In: Balch C, Houghton A, Sober AJ, Soong S, eds. Cutaneous Melanoma. St. Louis, MO: Quality Medical Publishing; 1998:463-473.

40. Satyamoorthy K, Meier F, Hsu M-Y, Berking C, Herlyn M. Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression. Cancer Metastasis Rev. 1999;18:401-405. PMID10721493

41. Hsu M-Y, Elder DE, Herlyn M. Melanoma: the Wistar melanoma (WM) cell lines. In: Masters JRW, Palsson B, eds. Human Cell Culture, Vol. 3. London: Kluwer Academic Publishing; 2000:259-274.

31


















42. Herlyn M, Berking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res. 2000;10:303-312. PMID10985664

43. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med Today. 2000;6:163-169. PMID10740255

44. Cascinelli N, Herlyn M, Schneeberger A, Kuwert C, Slominski A, Armstrong C, Belli F, Lukiewcz S, Maurer D, Ansel J, Stingl G, Saida T. What is the most promising strategy for the treatment of metastasizing melanoma? Exp Dermatol. 2000;9:439-451.

45. Herlyn M, Satyamoorthy K. Molecular biology of cutaneous melanoma. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:2003-2012.

46. Berking C, Herlyn M. Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol Histopathol. 2001;16:669-674. PMID11332722

47. Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box—new clues to apoptosis and drug resistance in melanoma. Trends Mol Med. 2001;7:191-194. PMID11325619

48. Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol. 2001;13:117-123. PMID11224709

49. Berking C, Herlyn M. Experimental inductin of human atypical melanocytic lesions and melanoma in ultraviolet-irradiated human skin grafted to immunodeficient mice. Methods Mol Med. 2001;61:71-84. PMID22323252

50. Kamb A, Herlyn M. Malignant melanoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Co.; 2001:967-977.

51. Hsu M-Y, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation. 2002;70:522-536. PMID12492494

52. Herlyn M, Padarathsingh M, Chin L, Hendrix M, Becker D, Nelson M, DeClerck Y, McCarthy J, Mohla S. New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section. Am J Pathol. 2002;161:1949-1957. PMID12414540

53. Bogenrieder T, Herlyn M. Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol. 2002;44:1-15. PMID12398996

54. Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther. 2002;1:14-17. PMID12170758

55. Li G, Satyamoorthy K, Herlyn M. Dynamics of cell interactions and communications during melanoma development. Crit Rev Oral Biol Med. 2002;13:62-70. PMID12097238

56. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol. 2002;3:35-43. PMID11905603

57. Herlyn M. Emerging concepts and technologies in melanoma research. Melanoma Res. 2002;12:3-8. PMID11828252

58. Herlyn M, Guerry D. First international melanoma research congress. Cancer Biol Ther. 2003;2:721-724. PMID14688485

59. Smalley KS, Herlyn M. The great escape: another way for melanoma to leave physiological control? J Invest Dermatol. 2003;121:xi-xii. PMID14632176

60. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524-6536. PMID14528277

61. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003;4:95-98. PMID12957284

62. Liu ZJ, Herlyn M. Slit-Robo: neuronal guides signal in tumor angiogenesis. Cancer Cell. 2003;4:1-2. PMID12892705

63. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 2003;24:335-342. PMID12810110

64. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene. 2003;22:3162-3171. PMID12789292

32





















65. Velazquez OC, Herlyn M. The vascular phenotype of melanoma metastasis. Clin Exp Metastasis. 2003;20:229-235. PMID12741681

66. Satyamoorthy K, Herlyn M. p16INK4A and familial melanoma. Methods Mol Biol. 2003;222:185-195. PMID12710687

67. Haass NK, Smalley KSM, Herlyn M. The role of altered cell-cell communication in melanoma progression. J Mol Histol. 2004;35:309-318. SPRINGER35354

68. Perlis C, Herlyn M. Recent advances in melanoma biology. Oncologist. 2004;9:182-187. PMID15047922

69. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005;18:150-159. PMID15892711

70. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005;10:2986-3001. PMID15970553

71. Hsu M-Y, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev. 2005;24:251-263. PMID15986135

72. Hsu M-Y, Li L, Herlyn M. Cultivation of normal human epidermal melanocytes in the absence of phorbol esters. Methods Mol Med. 2005;107:13-28. PMID15492362

73. Fang D, Herlyn M. The transformed phenotype of melanocytes. In: Nordlund JI, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J-P, eds. The Pigmentary System: Physiology and Pathophysiology. 2nd ed. Madden, MA: Wiley-Blackwell; 2006:489-496.

74. Herlyn M. Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int J Cancer. 2006;118:523-526. PMID16258898

75. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci. 2005;1059:16-25. PMID16382039

76. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc. 2005;10:153-163. PMID16358819

77. Smalley KS, Lioni M, Herlyn M. Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther. 2005;5:1069-1078. PMID16336098

78. Smalley KS, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol. 2005;15:451-459. PMID16043361

79. Smalley KS, Herlyn M. Towards the targeted therapy of melanoma. Mini Rev Med Chem. 2006;6:387-393. PMID16613575

80. Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LWK. Cancer interactions with the bone environment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol. 2006;168:1405-1412. PMID1665160

81. Smalley KSM, Lioni M, Herlyn M. Life isn’t flat: taking cancer biology to the next dimension. In Vitro Cellular & Develop Biol Animals. 2006;42:242-247. PMID17163781

82. Lee JT, Herlyn M. Microenvironment influences melanoma progression. J Cell Biochem. 2007;101:862-872. PMID17171636

83. Smalley KS, Herlyn M. Malignant melanoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Online Metabolic and Molecular Bases of Inherited Disease. Heidelberg: Springer; 2007:1-27.

84. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res. 2007;20:458-465. PMID17935489

85. Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D. Roadmap for new opportunities in melanoma research. Semin Oncol. 2007;34:566-576. PMID18086289

86. Zabierowski S, Herlyn M. Role of stem cells in melanoma progression: hopes for a better treatment. Expert Rev Dermatol. 2007;2:191-201.

87. Lee JT, Herlyn M. Old disease, new culprit: tumor stem cells in cancer. J Cell Physiol. 2007;213:603-609. PMID17873516

88. Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 2007;13:226-228. PMID1776275

33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16613575











http://dx.doi.org/10.1023/B:HIJO.0000032362.35354.bb




89. Smalley KSM, Lioni M, Noma K, Haass NK, Herlyn M. In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opinion Drug Discov. 2008;3:1-10. (PMC N/A)

90. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol. 2008;26:2890-2894. PMID18539969 (PMC N/A)

91. Roesch A, Herlyn M. Melanoma stem cells. In: Farrar W, ed. Cancer Stem Cells. Cambridge University Press; 2010:1-48. (PMC N/A)

92. Haass NK, Hoeller C, Herlyn M. Targeting signaling pathways—in the search of melanoma’s Achilles’ heel. In: Bar-Eli M, ed. Regulation of Gene Expression in the Tumor Environment. Springer; 2008:27-42. (PMC N/A)

93. Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep. 2008;10:439-446. PMID18706274 (PMC N/A)

94. Smalley K, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int J Cancer. 2009;124:1245-1250. PMID19089923 (PMC N/A)

95. Villanueva J, Herlyn M. Melanoma. In: Encyclopedia of Life Sciences (eLS). John Wiley & Sons; 2009. (PMC N/A)

96. Santiago-Walker A, Li L, Herlyn M. Melanocytes: from morphology to application. Skin Pharmacol Physiol. 2009;22:114-121. PMID19188759 (PMC N/A)

97. Herlyn M. Driving in the melanoma landscape. Exp Dermatol. 2009;18:506-508. PMID19366372 (PMC N/A)

98. Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenvironment. 2008;1:93-102. PMID19308688 (PMC2654351)

99. Zabierowski SE, Herlyn M. Embryonic stem cells as a model to study melanocyte development. Methods Mol Biol. 2010;584:301-316. PMID19907984 (PMC N/A)

100. Gaddipati H, Herlyn M. Melanoma: mutations in multiple pathways at the tumor-stroma interface. In: Thomas-Tikhoenenko A, ed. Cancer Genome and Tumor Microenvironment. New York, NY: Springer, 2010; 455-470. (PMC N/A)

101. Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M. Dermis-derived stem cells: a source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res. 2011;24:422-429. PMID21410654 (PMC N/A)

102. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step towards manageable disease. Clin Cancer Res. 2011;17:1658-1663. PMID21447722 (PMC3079374)

103. Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance cells. J Invest Dermatol. 2011;131:1600-1604. PMID21654838 PMC(3471358)

104. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71:7137-7140. PMID22131348 (PMCID3588168)

105. Zhang G, Herlyn M. Tumor microenvironment for melanoma cells. In: Bosserhoff A, ed. Melanoma Development. New York: Springer; 2011:297-308. (PMC N/A)

106. Herlyn M, Villanueva J. Sorting through the many opportunities for melanoma therapy. Pigm Cell Melanoma Res. 2011;24:975-7. PMID21899726 (PMC N/A)

107. Li L, Fukunaga-Kalabis M, Herlyn M. Isolation and cultivation of dermal stem cells that differentiate into functional melanocytes. Methods Mol Biol. 2012;806:15-29. PMID22057442 (PMC N/A)

108. Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark. 2011;9:267-286. PMID22112480 (PMC N/A)

109. Lee JT, Herlyn M. MEK’ing the most of p53 reactivation therapy in melanoma. J Invest Dermatol. 2012;132:263-265. PMID22241441 (PMC N/A)

110. Slipcevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala J Med Sci. 2012;117:237-243. PMID22339359 (PMC3339555)

111. Maurer M, Somasundaram R, Herlyn M, Wagner SN. Immunotargeting of tumor subpopulations in melanoma patients: a paradigm shift in therapy approaches. Oncoimmunology. 2012;1:1454-1456. PMID23243627 (PMC3518536)

34


112. Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Advances Pharmacol. 2012;65:335-359. PMID2259031 (PMC in Process by Elsevier)

113. Facombre N, Nakagawa H, Herlyn M, Basu D. Stem-like therapy and therapy resistance in squamous cell carcinoma. Advances in Pharmacol. 2012;65:359-365. PMID22959028 (PMC in Process by Elsevier)

115. Swoboda R, Herlyn M. There is a world beyond proteIn mutations: the role of nonocoding RNAs in melanomagenesis. Exp Dermatol. 2013;22:303-306. PMID23489578 (PMC3637432 [Available on 2014/5/1]; NIHMS445771)

116. Li L, Fukunaga-Kalabis M, Herlyn M. Isolation, characterization and differentiation of human multipotent dermal stem cells. Methods Mol Biol. 2013;989:235-246. PMID234838399

117. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Homen S, Topalian S, Van Dyke T, Herlyn M. The future of preclinical mouse models in melanoma treatment is now. Pigm Cell Mel Res. 2013;26:E8-E14. PMID23531109

118. Slipicevic A, Somasundaram S, Sproesser K, Herlyn M. Isolation of melanoma subpopulations using negative selection. Methods Mol Biol. 2014;1102:501-512. PMID24258995

119. Vultur A, Smalley K, Herlyn M. Melanoma. In: Gelman EP, Sawyer CL, Rauscher III FJ, eds. Molecular Oncology: Causes of Cancer and Targets for Treatment. West Nyack, NY: Cambridge University Press; 2014:698-703.

120. Liu J, Fukunaga-Kalabis M, Li L, Herlyn M. Developmental pathways activated in melanocytes and melanoma. Arch Biochem Biophys. 2014;563C:13-21. PMID25109840

121. Schadendorf D, Fisher D, Garbe C, Gershenwald JE, Grob J-J, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Melanoma. Nature Reviews, in press.

Research Publications, Non-Peer Reviewed1. Guerry D, Alexander MA, Fuhrer JP, Herlyn M, Mitchell KF. HLA-DR-dependent autologous T-cell

proliferation induced by cultured primary melanoma. In: Seji M, ed. Phenotypic Expression in Pigment Cells. Tokyo, Japan: University of Tokyo Press; 1981:547-553.

2. Mach JP, Forni M, Buchegger F, Carrel S, Ritschard J, Donath A, Herlyn M, Koprowski H. Use of radiolabeled monoclonal antibodies against colon carcinoma for photoscanning detection of tumors in patients. In: Raynaud C, ed. Nuclear Medicine and Biology IV. Paris, France: Pergamon Press; 1982: 2292-2294.

3. Holgersson J, Karlsson KA, Karlsson P, Ringqvist M, Stromberg N, Thurin J, Blaszczyk M, Herlyn M, Steplewski Z, Koprowski H. Mouse monoclonal antibodies with specificity for human melanoma cells are directed against hitherto unknown disialogangliosides. In: Chester MA, Heinegard D, Lundblad A, Svensson S, eds. Glycoconjugates. Lund-Ronneby, Sweden: Rahms; 1983:856-858.

4. Herlyn M, Blaszczyk M, Koprowski H. Immunodiagnosis of human solid tumors. In: Riethmueller G, Koprowski H, Kleinst SV, Munk K, eds. Genes and Antigens in Cancer Cells: The Monoclonal Antibody Approach, Vol. 19. Basel, Switzerland: S Karger Publications; 1984:160-170.

5. DeFreitas E, Suzuki H, Herlyn D, Lubeck M, Sears H, Herlyn M, Koprowski H. Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen. Curr Top Microbiol Immunol. 1985;75-89.

6. Herlyn M, Koprowski H. New tumor markers in human gastrointestinal cancer. In: Nakamura R, Vito WR, Tucker ESI, eds. Clinical Laboratory Molecular Analyses: New Strategies in Autoimmunity, Cancer and Virology. San Diego, CA: Grune and Stratton; 1985:129-143.

7. Herlyn M. Tumor markers in human colorectal carcinoma. In: Clinical Laboratory Molecular Analyses: Future Directions. San Diego, CA: Scripps Clinic and Research Foundation; 1985:86-92.

8. Herlyn M. Detection of tumor-associated antigens in sera of patients with early gastrointestinal malignancies. In: Chatal JF, Danis M, eds. Monoclonal Antibodies in Oncology: Clinical Application. Nantes, France: Nouvelles Editions Medicales Francaises; 1985:21-24.

9. Steplewski Z, Blaszczyk M, Herlyn D, Herlyn M, Koprowski H. Effector cells in ADCC with anti-breast cancer monoclonal antibodies. In: Ceriani RL, ed. Workshop on Monoclonal Antibodies and Breast Cancer. San Francisco, CA: Martinus Nijhoff Publishing; 1985:134-149.

35


10. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. CO 17-1A and related monoclonal antibodies: their production and characterization. Hybridoma. 1986;5(suppl 1):S3-10. PMID3744383

11. Clark WHJ, Herlyn M. Melanocyte differentiation. Lab Invest. 1987;57:600-601. 12. Herlyn M, Ross AH, Balaban G, Herlyn D, Thurin J, Rodeck U, Koprowski H. Cell biology of

melanoma and nonmalignant melanocytic lesions. In: Mackie RM, ed. Pigment Cell: Pathobiology of Melanoma. Karger, Basel, Switzerland; 1987:166-181.

13. Kath R, Rodeck U, Menssen HD, Mancianti ML, Linnenbach AJ, Elder DE, Herlyn M. Tumor progression in the human melanocytic system. Anticancer Res. 1989;9:865-872. PMID2554787

14. Mancianti ML, Herlyn M. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro. Carcinog Compr Surv. 1989;11:369-386. PMID2646021

15. Györfi T, Rodeck U, Herlyn M. Growth factors in melanoma. In: Biological Agents in the Treatment of Melanoma and Other Cancers; 1990:501-510; Proceedings of the International Conference, Newcastle, Australia.

16. Juhasz I, Herlyn M. Stage-related structures on melanoma cells. In: Hersey P, ed. Biological Agents in the Treatment of Melanoma and Other Cancers; 1990:256-267; Proceedings of the International Conference, Newcastle, Australia.

17. Rodeck U, Herlyn M. Growth regulation in normal and malignant melanocytes. In: Paukovits WR, ed. CRC Uniscience: Growth Regulation and Carcinogenesis. Boca Raton, FL: CRC Press; 1990:243-250.

18. Graeven U, Becker D, Herlyn M. Structural and functional characteristics of human melanoma. In: Pretlow TG, Pretlow TP, eds. Biochemical and Molecular Aspects of Selected Cancers. Orlando, FL: Academic Press; 1991:151-176.

19. Herlyn M, Houghton AN. Biology of melanocytes and melanoma. In: Balch C, Houghton A, Milton G, Sober A, eds. Cutaneous Melanoma. Philadelphia, PA: Lippincott Co.; 1991:82-92.

20. Litwack G, Robertson NM, Maksymowych AB, Herlyn M. Vitamin B6 and other inhibitors of glucocorticoid receptor function and cell-death of B16 melanoma cells. In: Jacobs MM, ed. Vitamins and Minerals in the Prevention and Treatment of Cancer. Boca Raton, FL: CRC Press; 1991:19-30.

21. Valyi-Nagy I, Rodeck U, Kath R, Mancianti ML, Clark WH, Herlyn M. The human melanocyte system as a model for studies on tumor progression. Basic Life Sci. 1991;57:315-326, discussion 326-318. PMID1814292

22. Houghton AN, Herlyn M, Ferrone S. Melanoma antigens. In: Balch C, Houghton A, Milton G, Sober A, eds. Cutaneous Melanoma. Philadelphia, PA: Lippincott Co; 1992:130-143.

23. Miller EJ, Herlyn M. The basement membrane in benign and malignant melanocytic lesions. In: Rabes H, Peters PE, Karger S, Munk K, eds. Contributions to Oncology. Basel, Switzerland: Karger; 1992:269-282.

24. Herlyn M. Molecular biology of the melanoma cell surface - translational opportunities. Hem/Onc Annals. 1993;1:251-255.

25. Györfi T, Herlyn M. Melanocyte and melanoma cell lines. In: Hay RJ, ed. The Atlas of Human Tumor Cell Lines. San Diego, CA; Academic Press; 1994:413-428.

26. Herlyn M. Molecular genetics, immunology and experimental pathology of melanoma. Report presented at: International Melanoma Conference; Brisbane, Australia: April 6-9, 1994. Melanoma Res. 1994;4:331-336. PMID7858419

27. Herlyn M, Schuchter L. Gene therapy of melanoma: strategies and perspectives. Skin Cancer J. 1996;14:92-93.

28. Puri N, Herlyn M. Melanoma: effects of growth factors. In: Miller SJ, Maloney ME, eds. Cutaneous Oncology: Pathophysiology, Diagnosis, and Treatment. Cambridge, MA: Blackwell Sci Inc.; 1996.

29. Dignat-George F, Bardin N, Combes V, Figarella-Branger D, Frances V, Herlyn M, Johnson JP, Lepidi H, Mutin M, Vewton J, Pickl WF, Schneemann M, Simmons D, Simoni J, Sampol J. CD146 (S-ENDO/Muc18). In: Kishimoto T, Goyert S, Kikutani H, et al, eds. Leucocyte Typing VI: White Cell Differentiation Ags. New York, NY: Garland Publishing Inc.; 1997:755-759.

30. Steplewski Z, Blaszczyk M, Herlyn D, Herlyn M, Koprowski H. Effector cells in ADCC with anti-breast cancer monoclonal antibodies. In: Ceriani RL, ed. Monoclonal Antibodies and Breast Cancer. Hingham, MA: Martinus Nijhoff Publishing; 1997:134-139.

36







31. Herlyn M. Endothelial cells as targets for tumor therapy. J Immunother. 1999;22:185. PMID10335478

32. Berking C, Herlyn M. The role of UV in melanomagenesis. In: Ortonne J-P, Ballotti R, eds. Mechanisms of Sun Tanning. London, England: Martin Dunitz Publications; 2002:327-332.

33. Bogenrieder T, Elder DE, Herlyn M. Molecular and cellular biology. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 4th ed. St. Louis, MO: Quality Medical Publications; 2003:713-751.

34. Ruiter GJ, Herlyn M. [Melanoma-stroma interactions and melanoma progression]. J Dtsch Dermatol Ges. 2003;1:773-776.

35. Smalley KS, Herlyn M. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. J Invest Dermatol. 2004;123:xvi-xvii. PMID15373800

36. Brafford P, Herlyn M. Gene expression profiling of melanoma cells−searching the haystack. J Transl Med. 2005;3:2. PMID15649323 (PMC545940)

37. Herlyn M. Metatastic melanoma cells: introduction. Cancer Metastasis Rev. 2005;24:193-194. PMID15986131

38. Li G, Herlyn M. Information sharing and collateral damage. Trends Mol Med. 2005;11:350-352. PMID16002338

39. Liu ZJ, Herlyn M. Molecular biology of cutaneous melanoma. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. 7th ed. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1745-1753.

40. Pinnix CC, Kogan M, Herlyn M. Melanoma stem cells: have we overlooked them? Mel Letter. 2005;23:3-4.

41. Lee JT, Herlyn M. Preventing metastasis: a LOX to learn. Cellscience Rev. 2006;3.42. Lee JT, Herlyn M. Embryogenesis meets tumorigenesis. Nature Med. 2006;12:882-884.

PMID16892028 43. Smalley KSM, Herlyn M. Is knowledge about the genetic and epigenetic alterations in melanoma

a basis for targeted therapy? Exp Dermatol. 2007;15:844-845.44. Smalley KSM, Herlyn M, Flaherty KT. Targeting BRAF/MEK inhibitors in melanoma therapy: new

hope or another false dawn? Exp Rev Derm. 2007;2:179-190.45. Herlyn M. Farming cells to rebuild skin and melanoma. Cancer Biol Ther. 2007;6:467-471.

PMID1737498346. Fukunaga-Kalabis M, Li L, Herlyn M. Three-dimensional culture of human skin. AACR Educational

Book from the AACR Annual Meeting; 2007:203-206.47. Fukunaga-Kalabis M, Herlyn M. Unraveling mysteries of the multifunctional protein SPARC. J

Invest Dermatol. 2007;127:2497-2498. PMID1793450148. Basu D, Herlyn M. Salmonella Typhimurium and a novel RNA interference vector for cancer gene

therapy. Cancer Biol Therap. 2008;7:151-152. PMID18347415 (PMC N/A)49. Zabierowski SE, Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell.

2008;13:185-187. PMID18328422 (PMC N/A)50. Possik P, Lee JT, Herlyn M. Transforming the melanocyte: more than just MAPK. Bioforum Eur.

2008;2:1-3. (PMC N/A)51. Lee JT, Brafford P, Herlyn M. Unraveling the mysteries of IGF-1 signaling in melanoma. J Invest

Dermatol. 2008;128:1358-1360. PMID18478012 (PMC N/A)52. Vultur A, Herlyn M. Cracking the system: melanoma complexitiy demands new therapeutic

approaches. Pigm Cell Mel Res. 2009;22:4-5. PMID19054340 (PMC N/A)53. Passague E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nature Med. 2009;15:23.

PMID19129778 (PMC N/A)54. Basu D, Herlyn M. Defining microenvironments within mouse models that enhance tumor

aggressiveness. Cancer Biol Ther. 2009;8:4. PMID19182538 (PMC N/A)55. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Sosman J.

Melanoma from bench to bedside. Meeting report from the 6th International Melanoma Research Congress. Pigm Cell Mel Res. 2010;23:14-26. PMID20025711 (PMC N/A)

56. Herlyn M, Fukunaga-Kalabis M. What is a good model for melanoma? J Invest Dermatol. 2010;130:911-912. PMID20231823 (PMC N/A)

37








57. Santiago-Walker A, Herlyn M. The ups and downs of transcription factors in melanoma. J Natl Cancer Inst. 2010;102:1103-1104. PMID20660367 (PMC N/A)

58. Vultur A, Villanueva J, Herlyn, M. BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell. 2010;18:301-302. (PMC N/A)

59. Herlyn M, Nathanson, K. Taking the guesswork out of uveal melanoma. New Engl J Med. 2010;263:2256-2257. PMID21083377 (PMC N/A)

60. Herlyn M, Bastian B. Pigm Cell Mel Res. 2010;23:834. PMID20973934 (PMC N/A)61. Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv

eradicate melanoma? Mol Ther. 2011;19:638-640. PMID21455210 (PMC3070110)62. Herlyn M. New dream team for melanoma therapy. Pigm Cell Mel Res. 2012;25:279-280.

PMID22462086 (PMC N/A)63. Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nature Med.

2012;18:853-854. PMID22673991 (PMC N/A)64. Herlyn M. Randy Lomax - the passionate melanoma advocate and champion of the Melanoma

Research Foundation. Pigm Cell Mel Res. 2012;25:832-833. PMID22702393 (PMC N/A)65. Räsänen K, Herlyn M. Paracrine signaling between carcinoma cells and mesenchymal

stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discov. 2012;2:775-779. PMID22969117 (PMC in Process by AACR)

66. Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanisms of drug resistance in melanoma side population. J Invest Dermatol. 2012;132:2317-2319. PMID22971921 (PMC in Process)

67. Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? J Invest Dermatol. 2012;132:2133-2134. PMID22895446 (PMC N/A)

69. Fukunaga-Kalabis M, Herlyn M. Cancer: complexion matters. Nature. 2012;491:342-343. PMID23123853 (PMC N/A)

70. Somasundaram R, Herlyn M. Relapse of melanoma after successful adoptive T-cell therapy: escape through inflammation-induced phenotypic melanoma plasticity. Pigm Cell Mel Res. 2013;26:2-4. PMID23387000 (PMC N/A)

71. Wang T, Somasundaram R, Herlyn M. Combination therapy of immunocytokines with Ipilumumab: a cure for melanoma? J Invest Dermatol. 2013;133:595-596. PMID23399823 (PMC N/A)

72. Wang T, Herlyn M. The macrophage: a new factor in UVR-induced melanomagenesis. J Invest Dermatol. 2013;133:1711-1713. PMID23760048

73. Vultur A, Herlyn M. Snapshot: melanoma. Cancer Cell. 2013;23:706. PMID23680152 74. Zhang G, Herlyn M. Linking SOX10 to slow-growth resistance phenotype. Cell Res.

2014;24:906-907. PMID2485395275. Somasundaram R, Herlyn M. Indomethacin to the rescue of TRAIL-resistant melanomas. J

Invest Dermatol. 2014;134:1198-1199. PMID2473233476. Geserick P, Somasundaram R, Sproesser K, Herlyn M. Isolation of melanoma cell subpopulations

using negative selection. Methods Mol Biol. 2014;1102:501-512. PMID2425899577. Slipicevic A, Herlyn M. KIT in melanoma: Many shades of grey. J Invest Dermatol. 2015;135:337-

8. PMID25573046

BooksHerlyn M. Molecular and Cellular Biology of Melanoma. Austin, TX: R.G. Landes Co; 1993.

PATENTS1. Detection of Colorectal Carcinoma

U.S. Patent #4,471,057Issued: September 11, 1984Inventors: Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn

2. Lewis Blood Group Phenotype AssayU.S. Patent #4,607,009Issued: August 19, 1986Inventors: Zenon Steplewski, Hilary Koprowski, and Meenhard Herlyn

38


3. Monoclonal Anti-Ornithine Decarboxylase Antibody and Method of Producing SameU.S. Patent #4,637,984Issued: January 20, 1987Inventors: Thomas O’Brien, Anthony Pegg, and Meenhard Herlyn

4. Diagnostic Method for Detection of Neural Crest DiseaseU.S. Patent #4,786,593Issued: November 22, 1988Inventors: Alonzo Ross, Hilary Koprowski, and Meenhard Herlyn

5. Monoclonal Antibodies against Melanoma-Associated Antigens and Hybrid Cell Lines Producing These Antibodies and Use ThereofU.S. Patent #4,849,509Issued: July 18, 1989Inventors: Jan Thurin, Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn

6. Monoclonal Antibody to EGF ReceptorU.S. Patent #5,470,571Issued: November 28, 1995Inventors: Meenhard Herlyn and Ulrich Rodeck

7. WT1 Monoclonal Antibodies and Methods of Use ThereofU.S. Patent #5, 622,835Issued: April 22, 1997Inventors: Meenhard Herlyn, Frank Rauscher, Ulrich Rodeck, and Jennifer Morris

8. Methods for Inducing Localized Vascular Development and Enhancing the Repair of a Wound in the Mammalian DermisU.S. Patent #6,486,133Issued: November 26, 2002 Inventors: Meenhard Herlyn, Mark Nesbit, and Kapaettu Satyamoorthy

9. Organotypic Culture of Colon and Usage ThereofU.S. Patent #7,217,570Issued: May 15, 2007Inventors: Meenhard Herlyn and Jiri Kalabis

10. Multipotent Adult Stem CellsU.S. Patent #60/671,025Issued: 2005Inventors: Xiao-Wei Xu, Hong Yu, Doug Fang, Meenhard Herlyn

11. Methods and Composition for Monitoring Cell Migration and Identifying Clinically Relevant Cytotoxic T Lymphocyte ActivityU.S. Patent #7,544,465Issued: June 9, 2009Inventors: Dorothee Herlyn, Meenhard Herlyn

12. Method for Dedifferentiating MelanocytesPCT Application No PCT/US2009/058950Issued: September 30, 2009 Inventors: Meenhard Herlyn and Susan Zabierowski

13. Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer39


PCT Application No: 61/232,069Issued: August 7, 2009Inventors: Meenhard Herlyn and Alexander Roesch

40

Documents

Professional Experience CV_3... · Web viewMeenhard Herlyn, D.V.M, D.Sc. Updated: 3/18/15. Home Address. 1223 Knox Road. Wynnewood, PA 19096. Office Address. The Wistar Institute